Cigna (CI) 10-Q 5 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Jul. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	1-38769
Entity Registrant Name	Cigna Corporation
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4991898
Entity Address, Address Line One	900 Cottage Grove Road
Entity Address, City or Town	Bloomfield
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06002
City Area Code	860
Local Phone Number	226-6000
Title of 12(b) Security	Common Stock, Par Value $0.01
Trading Symbol	CI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		340,107,539
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001739940

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues
Premiums	$ 10,323	$ 10,406	$ 20,537	$ 21,246
Net investment income	310	223	701	576
TOTAL REVENUES	43,131	39,265	84,102	77,734
Benefits and expenses
Pharmacy and other service costs	29,001	25,611	56,236	49,801
Medical costs and other benefit expenses	8,484	7,112	16,489	15,434
Selling, general and administrative expenses	2,996	3,407	6,275	6,805
Amortization of acquired intangible assets	503	496	998	994
TOTAL BENEFITS AND EXPENSES	40,984	36,626	79,998	73,034
Income (loss) from operations	2,147	2,639	4,104	4,700
Interest expense and other	(298)	(374)	(612)	(765)
Debt extinguishment costs	(10)	(14)	(141)	(199)
Net realized investment gains (losses)	59	38	60	(50)
Income before income taxes	1,898	2,289	3,411	3,686
TOTAL INCOME TAXES	422	529	764	737
Net income	1,476	1,760	2,647	2,949
Less: Net income attributable to noncontrolling interests	9	6	19	14
SHAREHOLDERS' NET INCOME	$ 1,467	$ 1,754	$ 2,628	$ 2,935
Shareholders’ net income per share
Basic (in dollars per share)	$ 4.30	$ 4.77	$ 7.62	$ 7.96
Diluted (in dollars per share)	$ 4.25	$ 4.73	$ 7.54	$ 7.88
Pharmacy revenues
Revenues
Revenues	$ 30,047	$ 26,564	$ 58,072	$ 51,662
Fees and other revenues
Revenues
Revenues	$ 2,451	$ 2,072	$ 4,792	$ 4,250

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 1,476	$ 1,760	$ 2,647	$ 2,949
Other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives	122	709	(151)	281
Net translation gains (losses) on foreign currencies	16	70	(103)	(105)
Postretirement benefits liability adjustment	15	(42)	33	(29)
Other comprehensive income (loss), net of tax	153	737	(221)	147
Total comprehensive income	1,629	2,497	2,426	3,096
Comprehensive income (loss) attributable to noncontrolling interests
Net income attributable to redeemable noncontrolling interest	3	4	8	8
Net income attributable to other noncontrolling interests	6	2	11	6
Other comprehensive (loss) attributable to redeemable noncontrolling interest	(1)	(2)	(5)	(6)
Total comprehensive income attributable to noncontrolling interests	8	4	14	8
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 1,621	$ 2,493	$ 2,412	$ 3,088

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Jun. 30, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents		$ 3,821	$ 10,182
Investments		1,305	1,331
Accounts receivable, net		15,462	12,191
Inventories		3,042	3,165
Other current assets		1,381	930
Total current assets		25,011	27,799
Long-term investments		23,622	23,262
Reinsurance recoverables		5,114	5,200
Deferred policy acquisition costs		3,397	3,385
Property and equipment		4,078	4,205
Goodwill		46,063	44,648
Other intangible assets		35,007	35,179
Other assets		2,654	2,687
Separate account assets		9,261	9,086
TOTAL ASSETS		154,207	155,451
Liabilities
Current insurance and contractholder liabilities		5,850	5,308
Pharmacy and other service costs payable		14,470	13,347
Accounts payable		5,647	5,478
Accrued expenses and other liabilities		7,212	8,515
Short-term debt		1,532	3,374
Total current liabilities		34,711	36,022
Non-current insurance and contractholder liabilities		16,665	16,844
Deferred tax liabilities, net		8,867	8,939
Other non-current liabilities		4,330	4,629
Long-term debt		31,606	29,545
Separate account liabilities		9,261	9,086
TOTAL LIABILITIES		105,440	105,065
Contingencies — Note 15
Redeemable noncontrolling interests		51	58
Shareholders’ equity
Common stock	[1]	4	4
Additional paid-in capital		29,403	28,975
Accumulated other comprehensive loss		(1,077)	(861)
Retained earnings		30,513	28,575
Less: Treasury stock, at cost		(10,134)	(6,372)
TOTAL SHAREHOLDERS’ EQUITY		48,709	50,321
Other noncontrolling interests		7	7
Total equity		48,716	50,328
Total liabilities and equity		$ 154,207	$ 155,451
[1]	Par value per share, $0.01; shares issued, 394 million as of June 30, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	394,000,000	390,000,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Adjustment upon Adoption	Shareholders’ Equity	Shareholders’ EquityAdjustment upon Adoption	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Retained EarningsAdjustment upon Adoption	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2019	$ 45,344	$ (30)	$ 45,338	$ (30)	$ 4	$ 28,306	$ (941)	$ 20,162	$ (30)	$ (2,193)	$ 6
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	309		309			393				(84)
Other comprehensive loss	153		153				153
Net income	2,941		2,935					2,935			6
Common dividends declared	(15)		(15)					(15)
Repurchase of common stock	(1,324)		(1,324)							(1,324)
Other transactions impacting noncontrolling interests	(7)										(7)
Balance at Jun. 30, 2020	47,371		47,366		4	28,699	(788)	23,052		(3,601)	5
Balance at Dec. 31, 2019	35
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(6)
Net income	8
Other transactions impacting noncontrolling interests	(3)
Balance at Jun. 30, 2020	$ 34
Change in Redeemable Noncontrolling Interests
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Common dividends declared (in dollars per share)	$ 0.04
Balance at Mar. 31, 2020	$ 45,086		45,079		4	28,554	(1,527)	21,298		(3,250)	7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	139		139			145				(6)
Other comprehensive loss	739		739				739
Net income	1,756		1,754					1,754			2
Repurchase of common stock	(345)		(345)							(345)
Other transactions impacting noncontrolling interests	(4)										(4)
Balance at Jun. 30, 2020	47,371		47,366		4	28,699	(788)	23,052		(3,601)	5
Balance at Mar. 31, 2020	35
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(2)
Net income	4
Other transactions impacting noncontrolling interests	(3)
Balance at Jun. 30, 2020	34
Balance at Dec. 31, 2020	50,328		50,321		4	28,975	(861)	28,575		(6,372)	7
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	342		342			431				(89)
Other comprehensive loss	(216)		(216)				(216)
Net income	2,639		2,628					2,628			11
Common dividends declared	(690)		(690)					(690)
Repurchase of common stock	(3,673)		(3,673)							(3,673)
Other transactions impacting noncontrolling interests	(14)		(3)			(3)					(11)
Balance at Jun. 30, 2021	48,716		48,709		4	29,403	(1,077)	30,513		(10,134)	7
Balance at Dec. 31, 2020	58
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(5)
Net income	8
Other transactions impacting noncontrolling interests	(10)
Balance at Jun. 30, 2021	$ 51
Change in Redeemable Noncontrolling Interests
Common dividends declared (in dollars per share)	$ 2
Balance at Mar. 31, 2021	$ 48,155		48,149		4	29,254	(1,231)	29,389		(9,267)	6
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans	150		150			152				(2)
Other comprehensive loss	154		154				154
Net income	1,473		1,467					1,467			6
Common dividends declared	(343)		(343)					(343)
Repurchase of common stock	(865)		(865)							(865)
Other transactions impacting noncontrolling interests	(8)		(3)			(3)					(5)
Balance at Jun. 30, 2021	48,716		$ 48,709		$ 4	$ 29,403	$ (1,077)	$ 30,513		$ (10,134)	$ 7
Balance at Mar. 31, 2021	59
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	(1)
Net income	3
Other transactions impacting noncontrolling interests	(10)
Balance at Jun. 30, 2021	$ 51
Change in Redeemable Noncontrolling Interests
Common dividends declared (in dollars per share)	$ 1

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 1	$ 2	$ 0.04

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities
Net income		$ 2,647	$ 2,949
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,446	1,387
Realized investment (gains) losses, net		(60)	50
Deferred income tax (benefit)		(80)	(259)
Debt extinguishment costs		141	199
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable		(3,233)	(2,121)
Inventories		124	(50)
Deferred policy acquisition costs		(117)	(177)
Reinsurance recoverable and Other assets		(416)	28
Insurance liabilities		677	483
Pharmacy and other service costs payable		1,123	1,655
Accounts payable and Accrued expenses and other liabilities		(1,643)	630
Other, net		188	387
NET CASH PROVIDED BY OPERATING ACTIVITIES		797	5,161
Proceeds from investments sold:
Debt securities and equity securities		852	1,638
Investment maturities and repayments:
Debt securities and equity securities		672	765
Commercial mortgage loans		96	10
Other sales, maturities and repayments (primarily short-term and other long-term investments)		897	664
Investments purchased or originated:
Debt securities and equity securities		(1,999)	(2,150)
Commercial mortgage loans		(129)	(13)
Other (primarily short-term and other long-term investments)		(1,136)	(934)
Property and equipment purchases, net		(500)	(523)
Acquisitions, net of cash acquired		(1,836)	0
Other, net		59	37
NET CASH (USED IN) INVESTING ACTIVITIES		(3,024)	(506)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds		96	529
Withdrawals and benefit payments from contractholder deposit funds		(96)	(483)
Net change in short-term debt		472	445
Payments for debt extinguishment		(136)	(212)
Repayment of long-term debt		(4,578)	(4,798)
Net proceeds on issuance of long-term debt		4,260	3,465
Repurchase of common stock		(3,710)	(1,324)
Issuance of common stock		290	229
Common stock dividend paid		(687)	(15)
Other, net		(24)	34
NET CASH (USED IN) FINANCING ACTIVITIES		(4,113)	(2,130)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash		(27)	(15)
Net (decrease) increase in cash, cash equivalents and restricted cash		(6,367)	2,510
Cash, cash equivalents and restricted cash January 1,	[1]	10,245	5,411
Cash, cash equivalents and restricted cash, June 30,		3,878	7,921
Cash reclassified to assets of business held for sale		0	(418)
Cash, cash equivalents, and restricted cash December 31, per Consolidated Balance Sheets	[2]	3,878	7,503
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds		1,473	190
Interest paid		$ 639	$ 743
[1]	Includes $743 million reported in Assets of business held for sale as of January 1, 2020. See table below for Cash, cash equivalents and restricted cash reconciliation.
[2]	See table below for Cash, cash equivalents and restricted cash reconciliation as of June 30, 2021 and 2020.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions		Jun. 30, 2021	Jun. 30, 2020
Statement of Cash Flows [Abstract]
Cash reclassified to assets of business held for sale		$ 0	$ 418
Cash and cash equivalents		3,821	7,185
Restricted cash and cash equivalents, included in other long-term investments		57	318
Total cash, cash equivalents and restricted cash and cash equivalents	[1]	$ 3,878	$ 7,503
[1]	See table below for Cash, cash equivalents and restricted cash reconciliation as of June 30, 2021 and 2020.

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Cigna Corporation, together with its subsidiaries (either individually or collectively referred to as “Cigna,” the “Company,” “we,” “our” or “us”) is a global health services organization with a mission of helping those we serve improve their health, well-being and peace of mind by making health care simple, affordable and predictable. Our subsidiaries offer a differentiated set of pharmacy, medical, dental and related products and services. The majority of these products are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna also offers commercial health and dental insurance, Medicare and Medicaid products and health, life and accident insurance coverages to individuals in the United States and selected international markets. In addition to these ongoing operations, Cigna also has certain run-off operations. The Company provides details of its reporting segments and recent changes below: In connection with the sale of the U.S. Group Disability and Life business on December 31, 2020, the remainder of our operations previously referred to as "Group Disability and Other" in our 2020 Form 10-K is now referred to as "Other Operations". There were no changes to the underlying business included in this category. Our business that offers group voluntary products and services was not sold to New York Life Insurance Company ("New York Life") and results of this business are reported in the U.S. Medical segment. In connection with the launch of Evernorth in the third quarter of 2020, two reporting segments were renamed. Health Services was renamed as Evernorth and Integrated Medical was renamed U.S. Medical. In addition, two of our operating segments were renamed: Commercial and Government were renamed U.S. Commercial and U.S. Government respectively. There were no changes to the underlying businesses reported in the segments. Evernorth includes a broad range of coordinated and point solution health services capabilities, as well as those from partners across the health care system, in pharmacy solutions, benefits management solutions, care solutions and intelligence solutions, which are provided to health plans, employers, government organizations and health care providers. U.S. Medical includes U.S. Commercial and U.S. Government businesses that provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental, vision, health advocacy programs and other products and services for insured and administrative services only ("ASO") clients. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors, Medicaid plans and individual health insurance plans both on and off the public exchanges. International Markets includes supplemental health, life and accident insurance products and health care coverage in our international markets, as well as health care benefits for globally mobile employees of multinational organizations. The remainder of our business operations are reported in Other Operations, consisting of the following: • Group Disability and Life . Prior to the sale of the U.S. Group Disability and Life business on December 31, 2020, this segment provided group long-term and short-term disability, group life, accident, voluntary and specialty insurance products and related services. • Corporate-Owned Life Insurance (“COLI”) offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for the purpose of financing employer-paid future benefit obligations. • Run-off businesses: • Reinsurance: predominantly comprised of guaranteed minimum death benefit (“GMDB”) and guaranteed minimum income benefit (“GMIB”) business effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska (“Berkshire”) in 2013. • Settlement Annuity business in run-off. • Individual Life Insurance and Annuity and Retirement Benefits businesses: deferred gains from the sales of these businesses. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, severance, certain overhead and project costs and intersegment eliminations for products and services sold between segments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Amounts recorded in the Consolidated Financial Statements necessarily reflect management’s estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.

Accounts Receivable, Net

Accounts Receivable, Net	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Accounts Receivable, Net	Accounts Receivable, Net The following amounts were included within Accounts receivable, net: (In millions) June 30, 2021 December 31, 2020 Noninsurance customer receivables $ 6,620 $ 5,534 Pharmaceutical manufacturers receivable 6,123 4,676 Insurance customer receivables 2,429 1,789 Other receivables 290 192 Total $ 15,462 $ 12,191

Mergers, Acquisitions and Dives

Mergers, Acquisitions and Divestitures	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Divestitures	Mergers, Acquisitions and DivestituresAcquisition of MDLIVE On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. ("MDLIVE"), a 24/7 virtual care platform. Combined with Cigna's previous held equity investment, Cigna now owns 100% of MDLIVE. As a result of the acquisition, Cigna recorded a realized gain on its existing equity investment. The acquisition of MDLIVE will enable Cigna's Evernorth segment to continue expanding access to virtual care and delivering a more affordable, convenient and connected care experience for consumers. The purchase price of $2.0 billion consisted of cash consideration. In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's preliminary estimates of their fair values and may change as additional information becomes available over the next several months. The estimated fair values of assets acquired and liabilities assumed as of the closing date were as follows: (In millions) Goodwill $ 1,437 Acquired intangible assets 627 Tangible assets acquired net of liabilities assumed 19 Total consideration transferred 2,083 Less: Fair value to Cigna's previously held equity interest (55) Total purchase price $ 2,028 Most of the goodwill is assigned to the Evernorth segment ($1.3 billion), with the remainder assigned to the U.S. Medical segment. Goodwill is not deductible for federal income tax purposes. The acquired intangible assets primarily consist of customer relationships ($577 million) as well as internal-use software, provider networks and a trade name. The fair value of the customer relationships and the amortization period were determined using an income approach that relies heavily on projected future net cash flows including key assumptions for customer attrition, margins and discount rates. The customer relationship intangible asset is amortized over a period of 17 years on an accelerated basis, reflecting the pattern in which Cigna expects to receive the benefits of the related cash flows. The results of MDLIVE have been included in the Company's Consolidated Financial Statements from the date of the acquisition. Revenues from MDLIVE and their results of operations were not material to Cigna's consolidated results of operations for the three or six months ended June 30, 2021. The pro forma effects of this acquisition for current and prior periods were not material to our consolidated results of operations.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share (“EPS”) Basic and diluted earnings per share were computed as follows: Three Months Ended June 30, 2021 June 30, 2020 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders’ net income $ 1,467 $ 1,467 $ 1,754 $ 1,754 Shares: Weighted average 341,479 341,479 367,396 367,396 Common stock equivalents 3,450 3,450 3,301 3,301 Total shares 341,479 3,450 344,929 367,396 3,301 370,697 EPS $ 4.30 $ (0.05) $ 4.25 $ 4.77 $ (0.04) $ 4.73 Six Months Ended June 30, 2021 June 30, 2020 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders’ net income $ 2,628 $ 2,628 $ 2,935 $ 2,935 Shares: Weighted average 344,845 344,845 368,918 368,918 Common stock equivalents 3,589 3,589 3,750 3,750 Total shares 344,845 3,589 348,434 368,918 3,750 372,668 EPS $ 7.62 $ (0.08) $ 7.54 $ 7.96 $ (0.08) $ 7.88 The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Anti-dilutive options 1.5 4.0 1.5 4.0

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt The outstanding amounts of debt and finance leases were as follows: (In millions) June 30, 2021 December 31, 2020 Short-term debt $78 million, 6.37% Notes due 6/2021 $ — $ 78 $1,000 million, Floating Rate Notes due 9/2021 — 999 $1,250 million, 3.4% Notes due 9/2021 — 1,249 Commercial paper 1,512 1,030 Other, including finance leases 20 18 Total short-term debt $ 1,532 $ 3,374 Long-term debt $277 million, 4% Notes due 2022 $ — $ 276 $973 million, 3.9% Notes due 2022 — 972 $500 million, 3.05% Notes due 2022 493 490 $17 million, 8.3% Notes due 2023 17 17 $63 million, 7.65% Notes due 2023 63 63 $700 million, Floating Rate Notes due 2023 699 698 $1,000 million, 3% Notes due 2023 980 975 $1,187 million, 3.75% Notes due 2023 1,184 2,181 $500 million, 0.613% Notes due 2024 498 — $1,000 million, 3.5% Notes due 2024 980 977 $900 million, 3.25% Notes due 2025 896 896 $2,200 million, 4.125% Notes due 2025 2,192 2,191 $1,500 million, 4.5% Notes due 2026 1,504 1,505 $800 million, 1.25% Notes due 2026 796 — $1,500 million, 3.4% Notes due 2027 1,416 1,410 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 595 $3,800 million, 4.375% Notes due 2028 3,781 3,780 $1,500 million, 2.4% Notes due 2030 1,490 1,489 $1,500 million, 2.375% Notes due 2031 (1) 1,507 — $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 (1) 2,191 2,180 $750 million, 3.2% Notes due 2040 743 742 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 490 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,465 1,465 $1,000 million, 3.875% Notes due 2047 988 988 $3,000 million, 4.9% Notes due 2048 2,967 2,966 $1,250 million, 3.4% Notes due 2050 1,235 1,235 $1,500 million , 3.4% Notes due 2051 1,476 — Other, including finance leases 31 36 Total long-term debt $ 31,606 $ 29,545 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 9 for further information about the Company's interest rate risk management and these derivative instruments. Debt Issuance and Redemption. In order to decrease future interest expense, mitigate future refinancing risk and raise proceeds for general corporate purposes, the Company entered into the following transactions during the six months ended June 30, 2021: • Debt issuance: On March 3, 2021, the Company issued $4.3 billion of new senior notes. The proceeds of this issuance were mainly used to redeem outstanding debt securities. The remaining proceeds are available for general corporate purposes. Interest on this debt is paid semi-annually. • Principal Maturity Date Interest Rate Net Proceeds $500 million March 15, 2024 0.613% $499 million $800 million March 15, 2026 1.250% $797 million $1,500 million March 15, 2031 2.375% $1,492 million $1,500 million March 15, 2051 3.400% $1,479 million • Debt redemption: During the first six months of 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities. The Company recorded a pre-tax loss of $141 million ($110 million after-tax), consisting primarily of premium payments. Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including for the purpose of providing liquidity support if necessary under our commercial paper program discussed below. As of June 30, 2021, there were no outstanding balances under these revolving credit agreements. In April 2021, Cigna entered into a $3.0 billion five-year revolving credit and letter of credit agreement that matures in April 2026 and a $1.0 billion three-year revolving credit agreement that matures in April 2024, which are diversified among 23 banks and replaced the five-year revolving credit and letter of credit agreement that was scheduled to mature in April 2023. Under the current agreements, Cigna can borrow up to $3.0 billion and $1.0 billion, respectively, for general corporate purposes, with up to $500 million available under the five-year facility for issuance of letters of credit. The revolving credit agreements also include an option to extend the termination date for an additional one-year period, subject to consent of the banks. Additionally, in April 2021, Cigna entered into a $1.0 billion 364-day revolving credit agreement that will mature in April 2022 and is diversified among 23 banks. This agreement replaced the prior $1.0 billion 364-day revolving credit agreement that was scheduled to expire in October 2021. Pursuant to this revolving credit agreement, Cigna can borrow up to $1.0 billion for general corporate purposes. The agreement includes the option to “term out” any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion. Each of the five-year facility, the three-year facility and the 364-day facility include an option to increase commitments in an aggregate amount of up to $1.5 billion across all three facilities. Each of the three facilities also contain customary covenants and restrictions including a financial covenant that the Company’s leverage ratio may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition. Commercial Paper. Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker dealers at any time not to exceed an aggregate amount of $4.25 billion as of June 30, 2021. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. In July 2021, our commercial paper program size was increased to $5.0 billion. The Company was in compliance with its debt covenants as of June 30, 2021.

Insurance and Contractholder Li

Insurance and Contractholder Liabilities	6 Months Ended
	Jun. 30, 2021
Insurance Loss Reserves [Abstract]
Insurance and Contractholder Liabilities	Insurance and Contractholder Liabilities A. Account Balances – Insurance and Contractholder Liabilities The Company’s insurance and contractholder liabilities were comprised of the following: June 30, 2021 December 31, 2020 June 30, 2020 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 357 $ 6,765 $ 7,122 $ 350 $ 6,823 $ 7,173 $ 7,689 Future policy benefits 314 9,217 9,531 327 9,317 9,644 9,945 Unearned premiums 511 401 912 485 394 879 930 Unpaid claims and claim expenses U.S. Medical 3,726 19 3,745 3,166 18 3,184 2,959 Other segments 942 263 1,205 980 292 1,272 6,150 Total 27,673 Insurance and contractholder liabilities classified as Liabilities of business held for sale (1) (6,549) Total insurance and contractholder liabilities $ 5,850 $ 16,665 $ 22,515 $ 5,308 $ 16,844 $ 22,152 $ 21,124 (1) Amounts classified as Liabilities of business held for sale primarily include $5.1 billion of unpaid claims, $758 million of contractholder deposit funds and $644 million of future policy benefits as of June 30, 2020. Insurance and contractholder liabilities expected to be paid within one year are classified as current. The total of incurred but not reported liabilities plus expected development on reported claims, including reported claims in process, was $3.4 billion at June 30, 2021 and $2.7 billion at June 30, 2020. Activity, net of intercompany transactions, in the unpaid claims liability for the U.S. Medical segment for the six months ended June 30 was as follows: Six Months Ended (In millions) June 30, 2021 June 30, 2020 Beginning balance $ 3,184 $ 2,892 Less: Reinsurance and other amounts recoverable 224 303 Beginning balance, net 2,960 2,589 Incurred costs related to: Current year 14,796 12,212 Prior years (181) (130) Total incurred 14,615 12,082 Paid costs related to: Current year 11,451 9,585 Prior years 2,572 2,284 Total paid 14,023 11,869 Ending balance, net 3,552 2,802 Add: Reinsurance and other amounts recoverable 193 157 Ending balance $ 3,745 $ 2,959 Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 for additional information on reinsurance. Variances in incurred costs related to prior years’ unpaid claims and claim expenses that resulted from the differences between actual experience and the Company’s key assumptions for the six months ended June 30 were as follows: Six Months Ended (Dollars in millions) June 30, 2021 June 30, 2020 $ % (1) $ % (2) Actual completion factors $ 55 0.2 % $ 50 0.2 % Medical cost trend 126 0.5 80 0.3 Total favorable variance $ 181 0.7 % $ 130 0.5 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2020. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2019. Favorable prior year development in both years reflects utilization of medical services that is lower than our estimates used to establish prior year reserves. Liability balance details. The liability details for unpaid claims and claim expenses are as follows: (In millions) June 30, 2021 June 30, 2020 Other Operations Group Disability and Life $ — $ 5,165 Other Operations 284 160 Total Other Operations 284 5,325 International Markets 921 825 Unpaid claims and claim expenses Other Operations and International Markets $ 1,205 $ 6,150 Activity in the Company’s liabilities for unpaid claims and claim expenses for International Markets and, prior to the sale, Group Disability and Life (see Note 4 for further information), is presented in the following table. Prior to the sale, the majority of the liability related to disability claims with long tailed payouts. See Note 9C to the Consolidated Financial Statements included in our 2020 Form 10-K for additional discussion of these disability reserves that are now sold. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been fully reinsured. Six Months Ended (In millions) June 30, 2021 June 30, 2020 (1) Beginning balance $ 963 $ 5,816 Less: Reinsurance 59 184 Beginning balance, net 904 5,632 Incurred claims related to: Current year 1,421 2,829 Prior years: Interest accretion — 81 All other incurred (51) (8) Total incurred 1,370 2,902 Paid claims related to: Current year 922 1,357 Prior years 467 1,353 Total paid 1,389 2,710 Foreign currency (21) (14) Ending balance, net 864 5,810 Add: Reinsurance 57 180 Ending balance $ 921 $ 5,990 (1) Includes unpaid claims amounts classified as Liabilities of business held for sale.

Reinsurance

Reinsurance	6 Months Ended
	Jun. 30, 2021
Reinsurance Disclosures [Abstract]
Reinsurance	Reinsurance The Company’s insurance subsidiaries enter into agreements with other insurance companies to assume and cede reinsurance. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance is also used to limit losses from large exposures and to permit recovery of a portion of direct or assumed losses. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. A. Reinsurance Recoverables The majority of the Company’s reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. Included in the table below are $227 million of current reinsurance recoverables that are reported in Other current assets as of June 30, 2021; as of December 31, 2020 there was $217 million of current reinsurance recoverables reported in Other current assets. The Company’s reinsurance recoverables as of June 30, 2021 are presented in the following table by range of external credit rating and collateral level. (in millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations Upper-medium grade and higher (1) $ — $ — $ 182 $ 182 Lower-medium grade (2) — — 64 64 Not rated 93 — 44 137 Total recoverables related to ongoing operations 93 — 290 383 Acquisition, disposition or runoff activities Upper-medium grade and higher (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,987 — 2,987 Berkshire 292 382 — 674 Prudential Retirement Insurance and Annuity 594 — — 594 Life Insurance Company of North America — 457 — 457 Other 226 17 18 261 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or runoff activities 1,112 3,856 21 4,989 Total $ 1,205 $ 3,856 $ 311 $ 5,372 Allowance for uncollectible reinsurance (31) Total reinsurance recoverables $ 5,341 (1) Includes A- equivalent and higher current ratings certified by a nationally recognized statistical rating organization ("NRSRO") (2) Includes BBB- to BBB+ equivalent current credit ratings certified by an NRSRO (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral’s fair value. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables. In the Company’s Consolidated Statements of Income, Premiums were reported net of amounts ceded to reinsurers and Medical costs and other benefit expenses were reported net of reinsurance recoveries in the following amounts: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Total ceded premiums $ 134 $ 117 $ 284 $ 245 Total reinsurance recoveries $ 133 $ 102 $ 281 $ 280 The Company entered into an agreement with Berkshire to effectively exit the GMDB and GMIB business via a reinsurance transaction in 2013. Berkshire reinsured 100% of the Company’s future claim payments in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit with approximately $3.2 billion remaining at June 30, 2021. GMDB is accounted for as assumed and ceded reinsurance and GMIB assets and liabilities are reported as derivatives at fair value as discussed below. GMIB assets are reported in Other current assets and Other assets and GMIB liabilities are reported in Accrued expenses and other liabilities and Other non-current liabilities. Assumptions used in fair value measurement for these assets and liabilities are discussed in Note 10 of the Company's 2020 Form 10-K. GMDB The GMDB exposure arises under annuities written by ceding companies that guarantee the benefit received at death. The Company’s exposure arises when the guaranteed minimum death benefit exceeds the fair value of the related mutual fund investments at the time of a contractholder’s death. The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) June 30, 2021 December 31, 2020 Account value $ 9,835 $ 9,523 Net amount at risk $ 1,450 $ 1,570 Number of contractholders (estimated) 175,000 185,000 GMIB The Company reinsured contracts with issuers of GMIB products. The Company’s exposure represents the excess of a contractually guaranteed amount over the level of variable annuity account values. Payment by the Company depends on the actual account value in the related underlying mutual funds and the level of interest rates when the contractholders elect to receive minimum income payments that can only occur within 30 days of a policy anniversary after the appropriate waiting period. The Company has purchased retrocessional coverage (“GMIB assets”) for these contracts including retrocessional coverage from Berkshire. GMIB liabilities totaling $604 million as of June 30, 2021 and $729 million as of December 31, 2020 are classified as Level 3 because fair value inputs are largely unobservable. There were three reinsurers covering 100% of the GMIB exposures as of June 30, 2021 and December 31, 2020 as follows: (In millions) Line of Business Reinsurer June 30, 2021 December 31, 2020 Collateral and Other Terms at June 30, 2021 GMIB Berkshire $ 295 $ 353 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 177 215 Liberty Re (Bermuda) Ltd. 159 190 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 631 $ 758 All reinsurers are rated A- equivalent and higher by an NRSRO. Amounts included in shareholders’ net income for GMIB assets and liabilities were not material for the three and six months ended June 30, 2021 or June 30, 2020.

Investments

Investments	6 Months Ended
	Jun. 30, 2021
Investments [Abstract]
Investments	InvestmentsCigna’s investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 10 for information about the valuation of the Company’s investment portfolio. Further information about our accounting policies for investment assets can be found in Note 11 of the Company's 2020 Form 10-K. The following table summarizes the Company's investments by category and current or long-term classification: June 30, 2021 December 31, 2020 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 904 $ 17,258 $ 18,162 $ 959 $ 17,172 $ 18,131 Equity securities — 530 530 — 501 501 Commercial mortgage loans 52 1,399 1,451 13 1,406 1,419 Policy loans — 1,341 1,341 — 1,351 1,351 Other long-term investments — 3,094 3,094 — 2,832 2,832 Short-term investments 349 — 349 359 — 359 Total $ 1,305 $ 23,622 $ 24,927 $ 1,331 $ 23,262 $ 24,593 The amortized cost and fair value by contractual maturity periods for debt securities were as follows at June 30, 2021: (In millions) Amortized Fair Due in one year or less $ 939 $ 945 Due after one year through five years 5,431 5,682 Due after five years through ten years 5,873 6,297 Due after ten years 3,947 4,761 Mortgage and other asset-backed securities 472 477 Total $ 16,662 $ 18,162 Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties. Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair June 30, 2021 Federal government and agency $ 288 $ — $ 107 $ — $ 395 State and local government 149 — 18 — 167 Foreign government 2,284 — 238 (22) 2,500 Corporate 13,469 (24) 1,234 (56) 14,623 Mortgage and other asset-backed 472 (12) 21 (4) 477 Total $ 16,662 $ (36) $ 1,618 $ (82) $ 18,162 Investments supporting liabilities of the Company’s run-off settlement annuity business (included in total above) (1) $ 2,307 $ (4) $ 727 $ (7) $ 3,023 December 31, 2020 Federal government and agency $ 334 $ — $ 122 $ — $ 456 State and local government 150 — 17 — 167 Foreign government 2,201 — 318 (8) 2,511 Corporate 13,108 (19) 1,506 (33) 14,562 Mortgage and other asset-backed 427 (7) 27 (12) 435 Total $ 16,220 $ (26) $ 1,990 $ (53) $ 18,131 Investments supporting liabilities of the Company’s run-off settlement annuity business (included in total above) (1) $ 2,282 $ (5) $ 838 $ (3) $ 3,112 (1) Net unrealized appreciation for these investments is excluded from accumulated other comprehensive income. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer’s industry or geographic region. The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of June 30, 2021 and December 31, 2020. June 30, 2021 December 31, 2020 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 2,178 $ 2,239 $ (61) 680 $ 1,026 $ 1,045 $ (19) 300 Below investment grade $ 439 $ 451 $ (12) 512 $ 381 $ 405 $ (24) 232 More than one year Investment grade $ 53 $ 55 $ (2) 12 $ 18 $ 18 $ — 6 Below investment grade $ 147 $ 154 $ (7) 32 $ 90 $ 100 $ (10) 33 Total $ 2,817 $ 2,899 $ (82) 1,236 $ 1,515 $ 1,568 $ (53) 571 Equity Securities The following table provides the values of the Company's equity security investments as of June 30, 2021 and December 31, 2020. The amount of impairments or value changes resulting from observable price changes on equity securities still held was not material to the financial statements as of June 30, 2021 or December 31, 2020. June 30, 2021 December 31, 2020 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 203 $ 208 $ 180 $ 202 Equity securities with no readily determinable fair value $ 232 $ 283 $ 225 $ 255 Hybrid equity securities $ 58 $ 39 $ 58 $ 44 Total $ 493 $ 530 $ 463 $ 501 Loan-to-value and debt service coverage ratio are the two most significant contributors to the credit quality ratings that the Company uses to evaluate and monitor credit risk in its commercial mortgage loan portfolio. The following table summarizes the credit risk profile of the Company’s commercial mortgage loan portfolio as of June 30, 2021 and December 31, 2020: (Dollars in millions) June 30, 2021 December 31, 2020 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 592 2.18 $ 533 2.28 60% to 79% 735 1.80 751 2.08 80% to 100% 130 1.47 141 1.33 Allowance for credit losses (6) (6) Total $ 1,451 1.93 60 % $ 1,419 2.08 61 % All commercial mortgage loans in the Company's portfolio are current as of June 30, 2021 and December 31, 2020. Other Long-Term Investments Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments: Carrying value as of (In millions) June 30, 2021 December 31, 2020 Real estate investments $ 1,078 $ 951 Securities partnerships 1,853 1,737 Other 163 144 Total $ 3,094 $ 2,832 The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of its long-term debt. The Company has written and purchased GMIB reinsurance contracts in its run-off reinsurance business that are accounted for as freestanding derivatives as discussed in Note 8. Derivatives in the Company’s separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate account policyholders. Derivative instruments used by the Company typically include foreign currency and interest rate swap contracts and foreign currency forward contracts. Swap contracts periodically exchange cash flows between fixed and variable interest rates or between two currencies for principal and interest. Foreign currency forward contracts require the Company to purchase a foreign currency in exchange for the functional currency of its operating unit at a future date. The Company manages the credit risk of these derivative instruments by diversifying its portfolio among approved dealers of high credit quality and through routine monitoring of credit risk exposures. While certain centrally-cleared derivative instruments require the posting of cash as an upfront margin, certain of the Company’s over-the-counter derivative instruments require either the Company or the counterparty to post collateral or demand immediate payment depending on the amount of the net liability position of the derivative instrument and predefined financial strength or credit rating thresholds. These collateral posting requirements vary by counterparty. The Company may incur a loss if dealers failed to perform under derivative contracts; however, collateral has been posted by dealers to cover substantially all of the net fair values owed at June 30, 2021 and December 31, 2020. The fair value of margin and collateral posted by the Company was not significant as of June 30, 2021 or December 31, 2020. The gross fair values of our derivative financial instruments are presented in Note 10. The following table summarizes the types and notional quantity of derivative instruments held by the Company. As of June 30, 2021 and December 31, 2020, the effects of these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive income into Shareholders' net income, as well as amounts excluded from the assessment of hedge effectiveness. Notional Value as of (In millions) June 30, 2021 December 31, 2020 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. Foreign currency swap contracts $ 1,040 $ 925 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 750 $ — Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in Euros, Korean Won and Taiwan Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts $ 686 $ 636 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company’s foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts $ 643 $ 538 Economic hedge: To hedge against the foreign exchange depreciation of certain foreign subsidiary earnings denominated in South Korean Won. The notional value of hedging instruments aligns with the U.S. dollar equivalent of hedged foreign-denominated earnings. Average rate option contracts $ 269 $ — The Company implemented two new hedging strategies during the second quarter of 2021 that are described in the above table and are accounted for as follows: • Fair value hedges of the interest rate exposure on the Company’s long-term debt: Using fair value hedge accounting, the fair values of the swap contracts are reported in Other assets, or Other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the Secured Overnight Financing Rate ("SOFR"). The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities. • Economic hedge against the depreciation of foreign subsidiary earnings due to changes in the quarterly average exchange rate: Fair values of average rate option contracts are reported in Other assets. Because hedge accounting is not applied, changes in fair value are reported currently in earnings in Fees and other revenues. Cash flows relating to these contracts are reported in Operating activities. As there have been no other changes to the types of derivative financial instruments the Company uses, refer to the Company’s 2020 Form 10-K for further discussion on our accounting policy. The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company’s separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ 60 $ 33 $ 70 $ 9 Credit loss (expense) recoveries (1) 6 (10) (49) Other investment asset write-downs — (1) — (10) Net realized investment gains (losses), before income taxes $ 59 $ 38 $ 60 $ (50) Net realized investment gains, excluding credit loss expense and asset write-downs for the six months ended June 30, 2021 was primarily driven by mark-to-market gains on equity securities and gains on the sales of real estate partnerships, partially offset by mark-to-market losses on derivatives. This activity for the six months ended June 30, 2020 primarily represent gains on sales of debt securities, partially offset by mark-to-market losses on derivatives and equity securities. Credit loss (expense) recoveries on invested assets reflect credit losses incurred on debt securities primarily relating to issuers in certain industries that have been impacted by the global COVID-19 pandemic. Realized gains and losses on equity securities still held at June 30, 2021 and 2020 were not material.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10 – Fair Value Measurements The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability’s fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company’s financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset’s or a liability’s classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument’s fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The following table provides information as of June 30, 2021 and December 31, 2020 about the Company’s financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company’s Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 Financial assets at fair value Debt securities Federal government and agency $ 155 $ 207 $ 240 $ 249 $ — $ — $ 395 $ 456 State and local government — — 167 167 — — 167 167 Foreign government — — 2,487 2,498 13 13 2,500 2,511 Corporate — — 13,956 13,878 667 684 14,623 14,562 Mortgage and other asset-backed — — 334 309 143 126 477 435 Total debt securities 155 207 17,184 17,101 823 823 18,162 18,131 Equity securities (1) 50 50 166 165 31 31 247 246 Short-term investments — — 348 325 — — 348 325 Derivative assets (2) — — 72 72 — — 72 72 Financial liabilities at fair value Derivative liabilities $ — $ — $ 45 $ 108 $ — $ — $ 45 $ 108 (1) Excludes certain equity securities that have no readily determinable fair value. (2) Derivative assets above include $1 million that are presented in the Short-term investments category disclosed in Note 9. See Note 9 for more information on our Derivative Financial Instruments. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company’s best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of June 30, 2021 and December 31, 2020. The range and weighted average basis point (“bps”) amounts for liquidity reflect the Company’s best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) June 30, 2021 December 31, 2020 Unobservable input June 30, 2021 June 30, 2021 December 31, 2020 Debt securities Corporate and government debt securities $ 680 $ 696 Liquidity 60 - 1720 (510) bps 60 - 1370 (470) bps Mortgage and other asset-backed securities 143 126 Liquidity 60 - 390 (90) bps 60 - 380 (80) bps Securities not priced by the Company (1) — 1 Total Level 3 debt securities $ 823 $ 823 (1) The fair values for these securities use single, unadjusted non-binding broker quotes not developed directly by the Company. Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and six months ended June 30, 2021 and 2020. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Six Months Ended (In millions) 2021 2020 2021 2020 Debt and Equity Securities Beginning balance $ 903 $ 766 $ 854 $ 555 Total gains (losses) included in shareholders’ net income (1) 17 (11) 5 Gains (losses) included in other comprehensive income 7 12 (9) (59) Gains (losses) required to adjust future policy benefits for settlement annuities (1) 1 7 (7) (3) Purchases, sales and settlements Purchases 42 2 71 64 Sales — — — (12) Settlements (9) (5) (25) (7) Total purchases, sales and settlements 33 (3) 46 45 Transfers into/(out of) Level 3 Transfers into Level 3 37 179 123 527 Transfers out of Level 3 (126) (118) (142) (210) Total transfers into/(out of) Level 3 (89) 61 (19) 317 Ending balance $ 854 $ 860 $ 854 $ 860 Total gains (losses) included in Shareholders’ net income attributable to instruments held at the reporting date $ (1) $ 16 $ (12) $ (1) Change in unrealized gains or losses included in Other comprehensive income for assets held at the end of the reporting period $ 7 $ 12 $ (9) $ (54) (1) Amounts do not accrue to shareholders. Total gains and losses included in Shareholders’ net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive income in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income. Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company’s best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases, and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2021 and 2020 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. Transfers into and out of Level 3 were higher in 2020 due to significant fluctuations in unobservable inputs experienced as a result of the uncertainty over the economic impacts related to COVID-19. See discussion under Quantitative Information about Unobservable Inputs above for more information. Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company’s Consolidated Statements of Income and Cash Flows. Fair values of Separate account assets at June 30, 2021 and December 31, 2020 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 Guaranteed separate accounts (See Note 15) $ 231 $ 226 $ 287 $ 297 $ — $ — $ 518 $ 523 Non-guaranteed separate accounts (1) 2,013 1,925 5,592 5,600 373 355 7,978 7,880 Subtotal $ 2,244 $ 2,151 $ 5,879 $ 5,897 $ 373 $ 355 8,496 8,403 Non-guaranteed separate accounts priced at NAV as a practical expedient (1) 765 683 Separate account assets per Consolidated Balance Sheets $ 9,261 $ 9,086 (1) Non-guaranteed separate accounts included $4.4 billion as of June 30, 2021 and $4.2 billion as of December 31, 2020 in assets supporting the Company’s pension plans, including $0.3 billion classified in Level 3 as of June 30, 2021 and December 31, 2020. Separate account assets classified in Level 3 primarily support Cigna’s pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three and six months ended June 30, 2021 or 2020. Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account’s ownership share of the equity of the investee (NAV as a practical expedient) including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna Pension Plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of June 30, 2021 Redemption Frequency Redemption Notice (In millions) June 30, 2021 December 31, 2020 Securities partnerships $ 483 $ 463 $ 270 Not applicable Not applicable Real estate funds 278 215 23 Quarterly 30 - 90 days Hedge funds 4 5 — Up to annually, varying by fund 30 - 90 days Total $ 765 $ 683 $ 293 As of June 30, 2021, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable, and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception. The following table includes the Company’s financial instruments not recorded at fair value that are subject to fair value disclosure requirements at June 30, 2021 and December 31, 2020. In addition to universal life products and finance leases, financial instruments that are carried in the Company’s Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy June 30, 2021 December 31, 2020 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,494 $ 1,451 $ 1,456 $ 1,419 Long-term debt, including current maturities, excluding finance leases Level 2 $ 36,076 $ 31,575 $ 37,676 $ 31,835

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2021
Variable Interest Entities [Abstract]
Variable Interest Entities	Variable Interest EntitiesWe perform ongoing qualitative analyses of our involvement with variable interest entities to determine if consolidation is required. The Company determined it was not a primary beneficiary in any material variable interest entity as of June 30, 2021 or December 31, 2020. The Company’s involvement with variable interest entities for which it is not the primary beneficiary has not changed materially from December 31, 2020. For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2020 Form 10-K. The Company has not provided, and does not intend to provide, financial support to any of these variable interest entities in excess of its maximum exposure.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) (“AOCI”) AOCI includes unrealized appreciation on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (See Note 9), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company’s share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized. Changes in the components of AOCI were as follows: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Securities and Derivatives Beginning balance $ 627 $ 547 $ 900 $ 975 Appreciation (depreciation) on securities and derivatives 170 920 (172) 340 Tax (expense) benefit (40) (196) 25 (69) Net appreciation (depreciation) on securities and derivatives 130 724 (147) 271 Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) (11) (19) (6) 13 Reclassification adjustment for tax expense (benefit) included in Shareholders’ net income 3 4 2 (3) Net (gains) losses reclassified from AOCI to Shareholders' net income (8) (15) (4) 10 Other comprehensive income (loss), net of tax 122 709 (151) 281 Ending balance $ 749 $ 1,256 $ 749 $ 1,256 Translation of foreign currencies Beginning balance $ (130) $ (446) $ (15) $ (275) Translation of foreign currencies 16 65 (98) (95) Tax (expense) benefit — 5 (5) (10) Other comprehensive income (loss), net of tax 16 70 (103) (105) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (1) (2) (5) (6) Shareholders' other comprehensive income (loss), net of tax 17 72 (98) (99) Ending balance $ (113) $ (374) $ (113) $ (374) Postretirement benefits liability Beginning balance $ (1,728) $ (1,628) $ (1,746) $ (1,641) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 19 18 39 36 Reclassification adjustment for settlement (Interest expense and other) 1 — 4 — Reclassification adjustment for tax expense (benefit) included in Shareholders’ net income (5) (4) (10) (9) Net adjustments reclassified from AOCI to Shareholders' net income 15 14 33 27 Valuation update — (73) — (73) Tax (expense) benefit — 17 — 17 Net change due to valuation update — (56) — (56) Other comprehensive income (loss), net of tax 15 (42) 33 (29) Ending balance $ (1,713) $ (1,670) $ (1,713) $ (1,670)

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Leases Operating and finance lease Right-of-Use (“ROU”) assets and lease liabilities were as follows: (In millions) June 30, 2021 December 31, 2020 Operating leases: Operating lease ROU assets $ 508 $ 552 Accrued expenses and other liabilities $ 149 $ 152 Other non-current liabilities 449 491 Total operating lease liabilities $ 598 $ 643 Finance leases: Property and equipment, gross $ 89 $ 98 Accumulated depreciation (40) (46) Property and equipment, net $ 49 $ 52 Short-term debt $ 20 $ 18 Long-term debt 31 36 Total finance lease liabilities $ 51 $ 54
Leases	Leases Operating and finance lease Right-of-Use (“ROU”) assets and lease liabilities were as follows: (In millions) June 30, 2021 December 31, 2020 Operating leases: Operating lease ROU assets $ 508 $ 552 Accrued expenses and other liabilities $ 149 $ 152 Other non-current liabilities 449 491 Total operating lease liabilities $ 598 $ 643 Finance leases: Property and equipment, gross $ 89 $ 98 Accumulated depreciation (40) (46) Property and equipment, net $ 49 $ 52 Short-term debt $ 20 $ 18 Long-term debt 31 36 Total finance lease liabilities $ 51 $ 54

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome Tax ExpenseThe 22.4% effective tax rate for the six months ended June 30, 2021 was higher than the 20.0% rate for the same period in 2020. This increase is primarily attributable to the absence of favorable items which reduced the rate in 2020, including settlements of uncertain tax positions and the remeasurement of deferred state income taxes due to changes in statutory rates and adjustments in apportionment factors; partially offset by the elimination of the nondeductible health insurer tax in 2021

Contingencies and Other Matters

Contingencies and Other Matters	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A. Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of June 30, 2021, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $450 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of June 30, 2021. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company’s consolidated results of operations, liquidity or financial condition. B. Certain Other Guarantees The Company had indemnification obligations as of June 30, 2021 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of June 30, 2021. C. Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company’s exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the six months ended June 30, 2021. D. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator’s filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health service business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company’s accruals for the matters discussed below under “Litigation Matters” and “Regulatory Matters” are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company’s results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation. Litigation Matters Risk Corridors and CSR Litigation with the Federal Government . As a result of a Supreme Court decision in April 2020, the Company filed suit in early May 2020 against the United States in the U.S. Court of Federal Claims seeking to recover two types of payments the Federal Government owes Cigna under the risk corridors and cost-sharing reduction (“CSR”) programs of The Patient Protection and Affordable Care Act. In aggregate, the complaint sought to recover more than $315 million: $120 million in risk corridors payments and more than $195 million in CSR payments. We received $120 million in payments in September 2020, which resolved our risk corridors claim. Our claim seeking recovery for CSR payments remains pending. Cigna Litigation with Anthem . In February 2017, the Company filed suit against Anthem, Inc. in the Delaware Court of Chancery (the “Chancery Court”) seeking, among other relief, payment of the $1.85 billion reverse termination fee under the parties’ 2015 merger agreement and damages. Anthem countersued, alleging its own claims for damages. A trial was held during the first quarter of 2019. In August 2020, the Chancery Court issued an opinion finding that, although Cigna breached its contractual obligation to use reasonable best efforts to support the Anthem/Cigna merger, its actions did not cause the merger to fail. The Court denied claims by both parties for damages and further denied Cigna’s claim for the reverse termination fee. The Company filed a Notice of Appeal with the Delaware Supreme Court on October 30, 2020, and sought reversal of the portion of the Chancery Court’s decision denying Cigna the reverse termination fee. Briefing on the appeal was completed on January 29, 2021 and oral arguments were held on April 14, 2021. On May 3, 2021, the Delaware Supreme Court issued an order affirming the decision of the Chancery Court. Express Scripts Litigation with Anthem . In March 2016, Anthem filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties’ rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Anthem also requested that the court enter declaratory judgment that Express Scripts is required to provide Anthem competitive benchmark pricing, that Anthem can terminate the agreement and that Express Scripts is required to provide Anthem with post-termination services at competitive benchmark pricing for one year following any termination by Anthem. Anthem claims it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Anthem and $150 million damages for service issues (“Anthem’s Allegations”). On April 19, 2016, in response to Anthem’s complaint, Express Scripts filed its answer denying Anthem’s Allegations in their entirety and asserting affirmative defenses and counterclaims against Anthem. The court subsequently granted Anthem’s motion to dismiss two of six counts of Express Scripts’ amended counterclaims. The current scheduling order runs through the completion of summary judgment briefing in November 2021. There is no tentative trial date. Regulatory Matters Civil Investigative Demand . The U.S. Department of Justice (“DOJ”) is conducting industry-wide investigations of Medicare Advantage organizations’ risk adjustment practices under Medicare Parts C and D including medical chart reviews and health exams. For certain Medicare Advantage organizations, those investigations have resulted in litigation. The Company has received information requests (civil investigative demands) from the DOJ (U.S. Attorney’s Offices for the Eastern District of Pennsylvania and the Southern District of New York ("SDNY")). We are continuing to cooperate with the DOJ and have responded and continue to respond to its requests. Additionally, in relation to the SDNY’s investigation, a qui tam action that was filed by a relator in the United States District Court for the Southern District of New York in 2017 was unsealed on August 6, 2020. The action asserts claims related to risk adjustment practices arising from certain health exams conducted as part of Cigna’s Medicare Advantage business. The DOJ has not intervened in the case at this time.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information See Note 1 for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy related transactions between the Evernorth and U.S. Medical segments. The Company uses "pre-tax adjusted income from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes they best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before taxes excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. The following tables present the special items recorded by the Company for the three and six months ended June 30, 2021 and 2020: Three Months Ended Six Months Ended (In millions) June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Debt extinguishment costs $ 9 $ 10 $ 11 $ 14 $ 110 $ 141 $ 151 $ 199 Integration and transaction-related costs 14 16 99 130 36 45 173 227 Charges associated with litigation matters — — — — (21) (27) 19 25 Charge for organizational efficiency plan — — — — — — 24 31 Contractual adjustment for a former client — — — — — — (66) (87) Total impact from special items $ 23 $ 26 $ 110 $ 144 $ 125 $ 159 $ 301 $ 395 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Three months ended June 30, 2021 Revenues from external customers $ 31,553 $ 9,689 $ 1,527 $ 52 $ — $ 42,821 Inter-segment revenues 1,034 595 — — (1,629) Net investment income 5 172 55 77 1 310 Total revenues 32,592 10,456 1,582 129 (1,628) 43,131 Net realized investment results from certain equity method investments — — (24) — — (24) Adjusted revenues $ 32,592 $ 10,456 $ 1,558 $ 129 $ (1,628) $ 43,107 Income (loss) before taxes $ 929 $ 1,060 $ 260 $ 19 $ (370) $ 1,898 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (6) — (5) — — (11) Net realized investment (gains) losses 2 (49) (30) (6) — (83) Amortization of acquired intangible assets 488 6 9 — — 503 Special items Debt extinguishment costs — — — — 10 10 Integration and transaction-related costs — — — — 16 16 Pre-tax adjusted income (loss) from operations $ 1,413 $ 1,017 $ 234 $ 13 $ (344) $ 2,333 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Three months ended June 30, 2020 Revenues from external customers $ 27,714 $ 8,684 $ 1,466 $ 1,178 $ — $ 39,042 Inter-segment revenues 885 504 — 6 (1,395) Net investment income 3 49 26 144 1 223 Total revenues 28,602 9,237 1,492 1,328 (1,394) 39,265 Net realized investment results from certain equity method investments — — (60) — — (60) Adjusted revenues $ 28,602 $ 9,237 $ 1,432 $ 1,328 $ (1,394) $ 39,205 Income (loss) before taxes $ 771 $ 1,543 $ 390 $ 129 $ (544) $ 2,289 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (3) — (5) — — (8) Net realized investment (gains) losses — (26) (73) 1 — (98) Amortization of acquired intangible assets 481 6 7 2 — 496 Special items Debt extinguishment costs — — — — 14 14 Integration and transaction-related costs — — — — 130 130 Pre-tax adjusted income (loss) from operations $ 1,249 $ 1,523 $ 319 $ 132 $ (400) $ 2,823 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Six Months Ended June 30, 2021 Revenues from external customers $ 60,972 $ 19,291 $ 3,026 $ 112 $ — $ 83,401 Inter-segment revenues 2,232 1,105 — — (3,337) Net investment income 8 422 114 156 1 701 Total revenues 63,212 20,818 3,140 268 (3,336) 84,102 Net realized investment results from certain equity method investments — — (10) — — (10) Adjusted revenues $ 63,212 $ 20,818 $ 3,130 $ 268 $ (3,336) $ 84,092 Income (loss) before taxes $ 1,678 $ 2,069 $ 486 $ 35 $ (857) $ 3,411 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) — (12) — — (23) Net realized investment (gains) losses (1) 4 (79) 3 2 — (70) Amortization of acquired intangible assets 965 14 19 — — 998 Special items Debt extinguishment costs — — — — 141 141 Integration and transaction-related costs — — — — 45 45 Charges associated with litigation matters — — — — (27) (27) Pre-tax adjusted income (loss) from operations $ 2,636 $ 2,004 $ 496 $ 37 $ (698) $ 4,475 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Six Months Ended June 30, 2020 Revenues from external customers $ 53,970 $ 17,952 $ 2,886 $ 2,350 $ — $ 77,158 Inter-segment revenues 1,859 970 — 11 (2,840) Net investment income 28 175 66 306 1 576 Total revenues 55,857 19,097 2,952 2,667 (2,839) 77,734 Net realized investment results from certain equity method investments — — (50) — — (50) Special item related to contractual adjustment for a former client (87) — — — — (87) Adjusted revenues $ 55,770 $ 19,097 $ 2,902 $ 2,667 $ (2,839) $ 77,597 Income (loss) before taxes $ 1,465 $ 2,683 $ 624 $ 201 $ (1,287) $ 3,686 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (7) — (10) — — (17) Net realized investment (gains) losses (1) — 22 (27) 5 — — Amortization of acquired intangible assets 960 17 14 3 — 994 Special items Debt extinguishment costs — — — — 199 199 Integration and transaction-related costs — — — — 227 227 Charges associated with litigation matters — — — — 25 25 Charge for organizational efficiency plan — — — — 31 31 Contractual adjustment for a former client (87) — — — — (87) Pre-tax adjusted income (loss) from operations $ 2,331 $ 2,722 $ 601 $ 209 $ (805) $ 5,058 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting. Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and six months ended June 30: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Products (Pharmacy revenues) (ASC 606) Network revenues $ 15,414 $ 13,090 $ 29,593 $ 25,232 Home delivery and specialty revenues 13,014 12,183 25,472 23,897 Other 1,619 1,291 3,007 2,533 Total pharmacy revenues $ 30,047 $ 26,564 $ 58,072 $ 51,662 Insurance premiums (ASC 944) U.S. Medical premiums U.S. Commercial Health Insurance 3,578 3,090 7,101 6,551 Stop loss 1,194 1,152 2,388 2,313 Other 308 283 618 572 U.S. Government Medicare Advantage 2,116 1,904 4,208 3,785 Medicare Part D 410 420 860 882 Other 1,227 1,063 2,365 2,129 Total U.S. Medical premiums 8,833 7,912 17,540 16,232 International Markets premiums 1,442 1,344 2,892 2,719 Domestic disability, life and accident premiums — 1,124 — 2,240 Other premiums 48 26 105 55 Total premiums 10,323 10,406 20,537 21,246 Services (ASC 606) Fees 2,345 1,979 4,672 4,133 Other external revenues 106 93 120 117 Total services 2,451 2,072 4,792 4,250 Total revenues from external customers $ 42,821 $ 39,042 $ 83,401 $ 77,158

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of Cigna Corporation and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Amounts recorded in the Consolidated Financial Statements necessarily reflect management’s estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Business Combinations	In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's preliminary estimates of their fair values and may change as additional information becomes available over the next several months.The fair value of the customer relationships and the amortization period were determined using an income approach that relies heavily on projected future net cash flows including key assumptions for customer attrition, margins and discount rates.
Unpaid Claims and Claims Expenses	Unpaid Claims and Claim Expenses – U.S. MedicalThis liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 8 for additional information on reinsuranceThe Company’s insurance subsidiaries enter into agreements with other insurance companies to assume and cede reinsurance. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance is also used to limit losses from large exposures and to permit recovery of a portion of direct or assumed losses. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral’s fair value. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.
Investments	Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer’s industry or geographic region.
Derivative Financial Instruments	The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of its long-term debt. The Company has written and purchased GMIB reinsurance contracts in its run-off reinsurance business that are accounted for as freestanding derivatives as discussed in Note 8. Derivatives in the Company’s separate accounts are excluded from the following discussion because associated gains and losses generally accrue directly to separate account policyholders. Derivative instruments used by the Company typically include foreign currency and interest rate swap contracts and foreign currency forward contracts. Swap contracts periodically exchange cash flows between fixed and variable interest rates or between two currencies for principal and interest. Foreign currency forward contracts require the Company to purchase a foreign currency in exchange for the functional currency of its operating unit at a future date. • Fair value hedges of the interest rate exposure on the Company’s long-term debt: Using fair value hedge accounting, the fair values of the swap contracts are reported in Other assets, or Other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by the Secured Overnight Financing Rate ("SOFR"). The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities. • Economic hedge against the depreciation of foreign subsidiary earnings due to changes in the quarterly average exchange rate: Fair values of average rate option contracts are reported in Other assets. Because hedge accounting is not applied, changes in fair value are reported currently in earnings in Fees and other revenues. Cash flows relating to these contracts are reported in Operating activities. As there have been no other changes to the types of derivative financial instruments the Company uses, refer to the Company’s 2020 Form 10-K for further discussion on our accounting policy.
Fair Value Measurements	The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability’s fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company’s financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset’s or a liability’s classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument’s fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company’s best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Total gains and losses included in Shareholders’ net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive income in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Separate Accounts	Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company’s Consolidated Statements of Income and Cash Flows.
AOCI	AOCI includes unrealized appreciation on securities and derivatives (excluding appreciation on investments supporting future policy benefit liabilities of the run-off settlement annuity business) (See Note 9), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company’s share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.
Commitment and Contingencies	The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator’s filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health service business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions. Pending litigation and legal or regulatory matters that the Company has identified with a reasonably possible material loss and certain other material litigation matters are described below. For those matters that the Company has identified with a reasonably possible material loss, the Company provides disclosure in the aggregate of accruals and range of loss, or a statement that such information cannot be estimated. The Company’s accruals for the matters discussed below under “Litigation Matters” and “Regulatory Matters” are not material. Due to numerous uncertain factors presented in these cases, it is not possible to estimate an aggregate range of loss (if any) for these matters at this time. In light of the uncertainties involved in these matters, there is no assurance that their ultimate resolution will not exceed the amounts currently accrued by the Company. An adverse outcome in one or more of these matters could be material to the Company’s results of operations, financial condition or liquidity for any particular period. The outcomes of lawsuits are inherently unpredictable and we may be unsuccessful in these ongoing litigation matters or any future claims or litigation.
Segment Information	A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy related transactions between the Evernorth and U.S. Medical segments. The Company uses "pre-tax adjusted income from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes they best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before taxes excluding net realized investment results, amortization of acquired intangible assets and special items. Cigna’s share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Accounts Receivable, Net	The following amounts were included within Accounts receivable, net: (In millions) June 30, 2021 December 31, 2020 Noninsurance customer receivables $ 6,620 $ 5,534 Pharmaceutical manufacturers receivable 6,123 4,676 Insurance customer receivables 2,429 1,789 Other receivables 290 192 Total $ 15,462 $ 12,191

Mergers, Acquisitions and Dispo

Mergers, Acquisitions and Dispositions (Tables)	6 Months Ended
	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Merger consideration and fair values of assets acquired and liabilities assumed	The estimated fair values of assets acquired and liabilities assumed as of the closing date were as follows: (In millions) Goodwill $ 1,437 Acquired intangible assets 627 Tangible assets acquired net of liabilities assumed 19 Total consideration transferred 2,083 Less: Fair value to Cigna's previously held equity interest (55) Total purchase price $ 2,028

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share were computed as follows: Three Months Ended June 30, 2021 June 30, 2020 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders’ net income $ 1,467 $ 1,467 $ 1,754 $ 1,754 Shares: Weighted average 341,479 341,479 367,396 367,396 Common stock equivalents 3,450 3,450 3,301 3,301 Total shares 341,479 3,450 344,929 367,396 3,301 370,697 EPS $ 4.30 $ (0.05) $ 4.25 $ 4.77 $ (0.04) $ 4.73 Six Months Ended June 30, 2021 June 30, 2020 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders’ net income $ 2,628 $ 2,628 $ 2,935 $ 2,935 Shares: Weighted average 344,845 344,845 368,918 368,918 Common stock equivalents 3,589 3,589 3,750 3,750 Total shares 344,845 3,589 348,434 368,918 3,750 372,668 EPS $ 7.62 $ (0.08) $ 7.54 $ 7.96 $ (0.08) $ 7.88
Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share	The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Anti-dilutive options 1.5 4.0 1.5 4.0

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Outstanding Amounts of Debt and Finance Leases	The outstanding amounts of debt and finance leases were as follows: (In millions) June 30, 2021 December 31, 2020 Short-term debt $78 million, 6.37% Notes due 6/2021 $ — $ 78 $1,000 million, Floating Rate Notes due 9/2021 — 999 $1,250 million, 3.4% Notes due 9/2021 — 1,249 Commercial paper 1,512 1,030 Other, including finance leases 20 18 Total short-term debt $ 1,532 $ 3,374 Long-term debt $277 million, 4% Notes due 2022 $ — $ 276 $973 million, 3.9% Notes due 2022 — 972 $500 million, 3.05% Notes due 2022 493 490 $17 million, 8.3% Notes due 2023 17 17 $63 million, 7.65% Notes due 2023 63 63 $700 million, Floating Rate Notes due 2023 699 698 $1,000 million, 3% Notes due 2023 980 975 $1,187 million, 3.75% Notes due 2023 1,184 2,181 $500 million, 0.613% Notes due 2024 498 — $1,000 million, 3.5% Notes due 2024 980 977 $900 million, 3.25% Notes due 2025 896 896 $2,200 million, 4.125% Notes due 2025 2,192 2,191 $1,500 million, 4.5% Notes due 2026 1,504 1,505 $800 million, 1.25% Notes due 2026 796 — $1,500 million, 3.4% Notes due 2027 1,416 1,410 $259 million, 7.875% Debentures due 2027 259 259 $600 million, 3.05% Notes due 2027 596 595 $3,800 million, 4.375% Notes due 2028 3,781 3,780 $1,500 million, 2.4% Notes due 2030 1,490 1,489 $1,500 million, 2.375% Notes due 2031 (1) 1,507 — $45 million, 8.3% Step Down Notes due 2033 45 45 $190 million, 6.15% Notes due 2036 190 190 $2,200 million, 4.8% Notes due 2038 (1) 2,191 2,180 $750 million, 3.2% Notes due 2040 743 742 $121 million, 5.875% Notes due 2041 119 119 $448 million, 6.125% Notes due 2041 490 490 $317 million, 5.375% Notes due 2042 315 315 $1,500 million, 4.8% Notes due 2046 1,465 1,465 $1,000 million, 3.875% Notes due 2047 988 988 $3,000 million, 4.9% Notes due 2048 2,967 2,966 $1,250 million, 3.4% Notes due 2050 1,235 1,235 $1,500 million , 3.4% Notes due 2051 1,476 — Other, including finance leases 31 36 Total long-term debt $ 31,606 $ 29,545 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 9 for further information about the Company's interest rate risk management and these derivative instruments.
Summary of Debt Issuances	The proceeds of this issuance were mainly used to redeem outstanding debt securities. The remaining proceeds are available for general corporate purposes. Interest on this debt is paid semi-annually. • Principal Maturity Date Interest Rate Net Proceeds $500 million March 15, 2024 0.613% $499 million $800 million March 15, 2026 1.250% $797 million $1,500 million March 15, 2031 2.375% $1,492 million $1,500 million March 15, 2051 3.400% $1,479 million

Insurance and Contractholder _2

Insurance and Contractholder Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Insurance Loss Reserves [Abstract]
Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses	The Company’s insurance and contractholder liabilities were comprised of the following: June 30, 2021 December 31, 2020 June 30, 2020 (In millions) Current Non-current Total Current Non-current Total Total Contractholder deposit funds $ 357 $ 6,765 $ 7,122 $ 350 $ 6,823 $ 7,173 $ 7,689 Future policy benefits 314 9,217 9,531 327 9,317 9,644 9,945 Unearned premiums 511 401 912 485 394 879 930 Unpaid claims and claim expenses U.S. Medical 3,726 19 3,745 3,166 18 3,184 2,959 Other segments 942 263 1,205 980 292 1,272 6,150 Total 27,673 Insurance and contractholder liabilities classified as Liabilities of business held for sale (1) (6,549) Total insurance and contractholder liabilities $ 5,850 $ 16,665 $ 22,515 $ 5,308 $ 16,844 $ 22,152 $ 21,124 (1) Amounts classified as Liabilities of business held for sale primarily include $5.1 billion of unpaid claims, $758 million of contractholder deposit funds and $644 million of future policy benefits as of June 30, 2020. Activity, net of intercompany transactions, in the unpaid claims liability for the U.S. Medical segment for the six months ended June 30 was as follows: Six Months Ended (In millions) June 30, 2021 June 30, 2020 Beginning balance $ 3,184 $ 2,892 Less: Reinsurance and other amounts recoverable 224 303 Beginning balance, net 2,960 2,589 Incurred costs related to: Current year 14,796 12,212 Prior years (181) (130) Total incurred 14,615 12,082 Paid costs related to: Current year 11,451 9,585 Prior years 2,572 2,284 Total paid 14,023 11,869 Ending balance, net 3,552 2,802 Add: Reinsurance and other amounts recoverable 193 157 Ending balance $ 3,745 $ 2,959 Liability balance details. The liability details for unpaid claims and claim expenses are as follows: (In millions) June 30, 2021 June 30, 2020 Other Operations Group Disability and Life $ — $ 5,165 Other Operations 284 160 Total Other Operations 284 5,325 International Markets 921 825 Unpaid claims and claim expenses Other Operations and International Markets $ 1,205 $ 6,150 Activity in the Company’s liabilities for unpaid claims and claim expenses for International Markets and, prior to the sale, Group Disability and Life (see Note 4 for further information), is presented in the following table. Prior to the sale, the majority of the liability related to disability claims with long tailed payouts. See Note 9C to the Consolidated Financial Statements included in our 2020 Form 10-K for additional discussion of these disability reserves that are now sold. Liabilities associated with Other Operations are excluded because they pertain to obligations for long-duration insurance contracts or, if short-duration, the liabilities have been fully reinsured. Six Months Ended (In millions) June 30, 2021 June 30, 2020 (1) Beginning balance $ 963 $ 5,816 Less: Reinsurance 59 184 Beginning balance, net 904 5,632 Incurred claims related to: Current year 1,421 2,829 Prior years: Interest accretion — 81 All other incurred (51) (8) Total incurred 1,370 2,902 Paid claims related to: Current year 922 1,357 Prior years 467 1,353 Total paid 1,389 2,710 Foreign currency (21) (14) Ending balance, net 864 5,810 Add: Reinsurance 57 180 Ending balance $ 921 $ 5,990
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses	Variances in incurred costs related to prior years’ unpaid claims and claim expenses that resulted from the differences between actual experience and the Company’s key assumptions for the six months ended June 30 were as follows: Six Months Ended (Dollars in millions) June 30, 2021 June 30, 2020 $ % (1) $ % (2) Actual completion factors $ 55 0.2 % $ 50 0.2 % Medical cost trend 126 0.5 80 0.3 Total favorable variance $ 181 0.7 % $ 130 0.5 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2020. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2019.

Reinsurance (Tables)

Reinsurance (Tables)	6 Months Ended
	Jun. 30, 2021
Reinsurance Disclosures [Abstract]
Reinsurance Recoverables by Range of External Credit Rating and Collateral Level	The Company’s reinsurance recoverables as of June 30, 2021 are presented in the following table by range of external credit rating and collateral level. (in millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations Upper-medium grade and higher (1) $ — $ — $ 182 $ 182 Lower-medium grade (2) — — 64 64 Not rated 93 — 44 137 Total recoverables related to ongoing operations 93 — 290 383 Acquisition, disposition or runoff activities Upper-medium grade and higher (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,987 — 2,987 Berkshire 292 382 — 674 Prudential Retirement Insurance and Annuity 594 — — 594 Life Insurance Company of North America — 457 — 457 Other 226 17 18 261 Not rated — 13 3 16 Total recoverables related to acquisition, disposition or runoff activities 1,112 3,856 21 4,989 Total $ 1,205 $ 3,856 $ 311 $ 5,372 Allowance for uncollectible reinsurance (31) Total reinsurance recoverables $ 5,341 (1) Includes A- equivalent and higher current ratings certified by a nationally recognized statistical rating organization ("NRSRO") (2) Includes BBB- to BBB+ equivalent current credit ratings certified by an NRSRO (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level
Effects of Reinsurance	In the Company’s Consolidated Statements of Income, Premiums were reported net of amounts ceded to reinsurers and Medical costs and other benefit expenses were reported net of reinsurance recoveries in the following amounts: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Total ceded premiums $ 134 $ 117 $ 284 $ 245 Total reinsurance recoveries $ 133 $ 102 $ 281 $ 280
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death	The following table presents the account value, net amount at risk and the number of contractholders for guarantees assumed by the Company in the event of death. The net amount at risk is the amount that the Company would have to pay if all contractholders died as of the specified date. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded. (Dollars in millions, excludes impact of reinsurance ceded) June 30, 2021 December 31, 2020 Account value $ 9,835 $ 9,523 Net amount at risk $ 1,450 $ 1,570 Number of contractholders (estimated) 175,000 185,000
Schedule of Derivative Assets at Fair Value	GMIB liabilities totaling $604 million as of June 30, 2021 and $729 million as of December 31, 2020 are classified as Level 3 because fair value inputs are largely unobservable. There were three reinsurers covering 100% of the GMIB exposures as of June 30, 2021 and December 31, 2020 as follows: (In millions) Line of Business Reinsurer June 30, 2021 December 31, 2020 Collateral and Other Terms at June 30, 2021 GMIB Berkshire $ 295 $ 353 100% were secured by assets in a trust. Sun Life Assurance Company of Canada 177 215 Liberty Re (Bermuda) Ltd. 159 190 100% were secured by assets in a trust. Total GMIB recoverables reported in Other current assets and Other assets $ 631 $ 758 All reinsurers are rated A- equivalent and higher by an NRSRO.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Investments [Abstract]
Investments by category and current or long-term classification	The following table summarizes the Company's investments by category and current or long-term classification: June 30, 2021 December 31, 2020 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 904 $ 17,258 $ 18,162 $ 959 $ 17,172 $ 18,131 Equity securities — 530 530 — 501 501 Commercial mortgage loans 52 1,399 1,451 13 1,406 1,419 Policy loans — 1,341 1,341 — 1,351 1,351 Other long-term investments — 3,094 3,094 — 2,832 2,832 Short-term investments 349 — 349 359 — 359 Total $ 1,305 $ 23,622 $ 24,927 $ 1,331 $ 23,262 $ 24,593
Debt Securities by Contractual Maturity	The amortized cost and fair value by contractual maturity periods for debt securities were as follows at June 30, 2021: (In millions) Amortized Fair Due in one year or less $ 939 $ 945 Due after one year through five years 5,431 5,682 Due after five years through ten years 5,873 6,297 Due after ten years 3,947 4,761 Mortgage and other asset-backed securities 472 477 Total $ 16,662 $ 18,162
Gross Unrealized Appreciation (Depreciation) on Debt Securities	Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair June 30, 2021 Federal government and agency $ 288 $ — $ 107 $ — $ 395 State and local government 149 — 18 — 167 Foreign government 2,284 — 238 (22) 2,500 Corporate 13,469 (24) 1,234 (56) 14,623 Mortgage and other asset-backed 472 (12) 21 (4) 477 Total $ 16,662 $ (36) $ 1,618 $ (82) $ 18,162 Investments supporting liabilities of the Company’s run-off settlement annuity business (included in total above) (1) $ 2,307 $ (4) $ 727 $ (7) $ 3,023 December 31, 2020 Federal government and agency $ 334 $ — $ 122 $ — $ 456 State and local government 150 — 17 — 167 Foreign government 2,201 — 318 (8) 2,511 Corporate 13,108 (19) 1,506 (33) 14,562 Mortgage and other asset-backed 427 (7) 27 (12) 435 Total $ 16,220 $ (26) $ 1,990 $ (53) $ 18,131 Investments supporting liabilities of the Company’s run-off settlement annuity business (included in total above) (1) $ 2,282 $ (5) $ 838 $ (3) $ 3,112 (1) Net unrealized appreciation for these investments is excluded from accumulated other comprehensive income.
Summary of Debt Securities with a Decline in Fair Value	The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. These debt securities are primarily corporate securities with a decline in fair value that reflects an increase in market yields since purchase. Our allowance for credit losses on debt securities was not material as of June 30, 2021 and December 31, 2020. June 30, 2021 December 31, 2020 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 2,178 $ 2,239 $ (61) 680 $ 1,026 $ 1,045 $ (19) 300 Below investment grade $ 439 $ 451 $ (12) 512 $ 381 $ 405 $ (24) 232 More than one year Investment grade $ 53 $ 55 $ (2) 12 $ 18 $ 18 $ — 6 Below investment grade $ 147 $ 154 $ (7) 32 $ 90 $ 100 $ (10) 33 Total $ 2,817 $ 2,899 $ (82) 1,236 $ 1,515 $ 1,568 $ (53) 571
Equity Security Investments	The following table provides the values of the Company's equity security investments as of June 30, 2021 and December 31, 2020. The amount of impairments or value changes resulting from observable price changes on equity securities still held was not material to the financial statements as of June 30, 2021 or December 31, 2020. June 30, 2021 December 31, 2020 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 203 $ 208 $ 180 $ 202 Equity securities with no readily determinable fair value $ 232 $ 283 $ 225 $ 255 Hybrid equity securities $ 58 $ 39 $ 58 $ 44 Total $ 493 $ 530 $ 463 $ 501
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio	The following table summarizes the credit risk profile of the Company’s commercial mortgage loan portfolio as of June 30, 2021 and December 31, 2020: (Dollars in millions) June 30, 2021 December 31, 2020 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 592 2.18 $ 533 2.28 60% to 79% 735 1.80 751 2.08 80% to 100% 130 1.47 141 1.33 Allowance for credit losses (6) (6) Total $ 1,451 1.93 60 % $ 1,419 2.08 61 %
Carrying Value Information for Other Long-Term Investments	The following table provides the carrying value information for these investments: Carrying value as of (In millions) June 30, 2021 December 31, 2020 Real estate investments $ 1,078 $ 951 Securities partnerships 1,853 1,737 Other 163 144 Total $ 3,094 $ 2,832
Summary of Derivative Instruments Held	The following table summarizes the types and notional quantity of derivative instruments held by the Company. As of June 30, 2021 and December 31, 2020, the effects of these individual hedging strategies were not material to the Consolidated Financial Statements, including gains or losses reclassified from Accumulated other comprehensive income into Shareholders' net income, as well as amounts excluded from the assessment of hedge effectiveness. Notional Value as of (In millions) June 30, 2021 December 31, 2020 Purpose Type of Instrument Fair value hedge: To hedge the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. Foreign currency swap contracts $ 1,040 $ 925 Fair value hedge: To convert a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Interest rate swap contracts $ 750 $ — Net investment hedge: To reduce the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in Euros, Korean Won and Taiwan Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts $ 526 $ 526 Foreign currency forward contracts $ 686 $ 636 Economic hedge: To hedge the foreign exchange-related changes in fair value of U.S. dollar-denominated investment assets to reflect the local currency for the Company’s foreign subsidiary in South Korea. The notional value of hedging instruments generally aligns with the fair value of the hedged investments. Foreign currency forward contracts $ 643 $ 538 Economic hedge: To hedge against the foreign exchange depreciation of certain foreign subsidiary earnings denominated in South Korean Won. The notional value of hedging instruments aligns with the U.S. dollar equivalent of hedged foreign-denominated earnings. Average rate option contracts $ 269 $ —
Realized Gains and Losses on Investments	The following realized gains and losses on investments exclude amounts required to adjust future policy benefits for the run-off settlement annuity business (consistent with accounting for a premium deficiency), as well as realized gains and losses attributed to the Company’s separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Net realized investment gains (losses), excluding credit loss expense and asset write-downs $ 60 $ 33 $ 70 $ 9 Credit loss (expense) recoveries (1) 6 (10) (49) Other investment asset write-downs — (1) — (10) Net realized investment gains (losses), before income taxes $ 59 $ 38 $ 60 $ (50)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Financial Assets and Financial Liabilities Carried at Fair Value	The following table provides information as of June 30, 2021 and December 31, 2020 about the Company’s financial assets and liabilities carried at fair value. Separate account assets are also recorded at fair value on the Company’s Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to policyholders. (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 As of June 30, 2021 As of December 31, 2020 Financial assets at fair value Debt securities Federal government and agency $ 155 $ 207 $ 240 $ 249 $ — $ — $ 395 $ 456 State and local government — — 167 167 — — 167 167 Foreign government — — 2,487 2,498 13 13 2,500 2,511 Corporate — — 13,956 13,878 667 684 14,623 14,562 Mortgage and other asset-backed — — 334 309 143 126 477 435 Total debt securities 155 207 17,184 17,101 823 823 18,162 18,131 Equity securities (1) 50 50 166 165 31 31 247 246 Short-term investments — — 348 325 — — 348 325 Derivative assets (2) — — 72 72 — — 72 72 Financial liabilities at fair value Derivative liabilities $ — $ — $ 45 $ 108 $ — $ — $ 45 $ 108 (1) Excludes certain equity securities that have no readily determinable fair value. (2) Derivative assets above include $1 million that are presented in the Short-term investments category disclosed in Note 9. See Note 9 for more information on our Derivative Financial Instruments.
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities	The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities as of June 30, 2021 and December 31, 2020. The range and weighted average basis point (“bps”) amounts for liquidity reflect the Company’s best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions ) June 30, 2021 December 31, 2020 Unobservable input June 30, 2021 June 30, 2021 December 31, 2020 Debt securities Corporate and government debt securities $ 680 $ 696 Liquidity 60 - 1720 (510) bps 60 - 1370 (470) bps Mortgage and other asset-backed securities 143 126 Liquidity 60 - 390 (90) bps 60 - 380 (80) bps Securities not priced by the Company (1) — 1 Total Level 3 debt securities $ 823 $ 823 (1) The fair values for these securities use single, unadjusted non-binding broker quotes not developed directly by the Company.
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value	The following table summarizes the changes in financial assets and financial liabilities classified in Level 3 for the three and six months ended June 30, 2021 and 2020. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended For the Six Months Ended (In millions) 2021 2020 2021 2020 Debt and Equity Securities Beginning balance $ 903 $ 766 $ 854 $ 555 Total gains (losses) included in shareholders’ net income (1) 17 (11) 5 Gains (losses) included in other comprehensive income 7 12 (9) (59) Gains (losses) required to adjust future policy benefits for settlement annuities (1) 1 7 (7) (3) Purchases, sales and settlements Purchases 42 2 71 64 Sales — — — (12) Settlements (9) (5) (25) (7) Total purchases, sales and settlements 33 (3) 46 45 Transfers into/(out of) Level 3 Transfers into Level 3 37 179 123 527 Transfers out of Level 3 (126) (118) (142) (210) Total transfers into/(out of) Level 3 (89) 61 (19) 317 Ending balance $ 854 $ 860 $ 854 $ 860 Total gains (losses) included in Shareholders’ net income attributable to instruments held at the reporting date $ (1) $ 16 $ (12) $ (1) Change in unrealized gains or losses included in Other comprehensive income for assets held at the end of the reporting period $ 7 $ 12 $ (9) $ (54) (1) Amounts do not accrue to shareholders.
Fair Values of Separate Account Assets	Fair values of Separate account assets at June 30, 2021 and December 31, 2020 were as follows: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 June 30, 2021 December 31, 2020 Guaranteed separate accounts (See Note 15) $ 231 $ 226 $ 287 $ 297 $ — $ — $ 518 $ 523 Non-guaranteed separate accounts (1) 2,013 1,925 5,592 5,600 373 355 7,978 7,880 Subtotal $ 2,244 $ 2,151 $ 5,879 $ 5,897 $ 373 $ 355 8,496 8,403 Non-guaranteed separate accounts priced at NAV as a practical expedient (1) 765 683 Separate account assets per Consolidated Balance Sheets $ 9,261 $ 9,086 (1) Non-guaranteed separate accounts included $4.4 billion as of June 30, 2021 and $4.2 billion as of December 31, 2020 in assets supporting the Company’s pension plans, including $0.3 billion classified in Level 3 as of June 30, 2021 and December 31, 2020.
Additional Information on Separate Account Assets Priced at NAV	Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account’s ownership share of the equity of the investee (NAV as a practical expedient) including changes in the fair values of its underlying investments. Substantially all of these assets support the Cigna Pension Plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of June 30, 2021 Redemption Frequency Redemption Notice (In millions) June 30, 2021 December 31, 2020 Securities partnerships $ 483 $ 463 $ 270 Not applicable Not applicable Real estate funds 278 215 23 Quarterly 30 - 90 days Hedge funds 4 5 — Up to annually, varying by fund 30 - 90 days Total $ 765 $ 683 $ 293
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value	The following table includes the Company’s financial instruments not recorded at fair value that are subject to fair value disclosure requirements at June 30, 2021 and December 31, 2020. In addition to universal life products and finance leases, financial instruments that are carried in the Company’s Consolidated Financial Statements at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy June 30, 2021 December 31, 2020 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,494 $ 1,451 $ 1,456 $ 1,419 Long-term debt, including current maturities, excluding finance leases Level 2 $ 36,076 $ 31,575 $ 37,676 $ 31,835

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Jun. 30, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in the Components of AOCI	Changes in the components of AOCI were as follows: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Securities and Derivatives Beginning balance $ 627 $ 547 $ 900 $ 975 Appreciation (depreciation) on securities and derivatives 170 920 (172) 340 Tax (expense) benefit (40) (196) 25 (69) Net appreciation (depreciation) on securities and derivatives 130 724 (147) 271 Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses) (11) (19) (6) 13 Reclassification adjustment for tax expense (benefit) included in Shareholders’ net income 3 4 2 (3) Net (gains) losses reclassified from AOCI to Shareholders' net income (8) (15) (4) 10 Other comprehensive income (loss), net of tax 122 709 (151) 281 Ending balance $ 749 $ 1,256 $ 749 $ 1,256 Translation of foreign currencies Beginning balance $ (130) $ (446) $ (15) $ (275) Translation of foreign currencies 16 65 (98) (95) Tax (expense) benefit — 5 (5) (10) Other comprehensive income (loss), net of tax 16 70 (103) (105) Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests (1) (2) (5) (6) Shareholders' other comprehensive income (loss), net of tax 17 72 (98) (99) Ending balance $ (113) $ (374) $ (113) $ (374) Postretirement benefits liability Beginning balance $ (1,728) $ (1,628) $ (1,746) $ (1,641) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 19 18 39 36 Reclassification adjustment for settlement (Interest expense and other) 1 — 4 — Reclassification adjustment for tax expense (benefit) included in Shareholders’ net income (5) (4) (10) (9) Net adjustments reclassified from AOCI to Shareholders' net income 15 14 33 27 Valuation update — (73) — (73) Tax (expense) benefit — 17 — 17 Net change due to valuation update — (56) — (56) Other comprehensive income (loss), net of tax 15 (42) 33 (29) Ending balance $ (1,713) $ (1,670) $ (1,713) $ (1,670)

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities	Operating and finance lease Right-of-Use (“ROU”) assets and lease liabilities were as follows: (In millions) June 30, 2021 December 31, 2020 Operating leases: Operating lease ROU assets $ 508 $ 552 Accrued expenses and other liabilities $ 149 $ 152 Other non-current liabilities 449 491 Total operating lease liabilities $ 598 $ 643 Finance leases: Property and equipment, gross $ 89 $ 98 Accumulated depreciation (40) (46) Property and equipment, net $ 49 $ 52 Short-term debt $ 20 $ 18 Long-term debt 31 36 Total finance lease liabilities $ 51 $ 54

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Summary of Special Items	The following tables present the special items recorded by the Company for the three and six months ended June 30, 2021 and 2020: Three Months Ended Six Months Ended (In millions) June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Description of Special Item Charges (Benefits) and Financial Statement Line Item(s) After-tax Before-tax After-tax Before-tax After-tax Before-tax After-tax Before-tax Debt extinguishment costs $ 9 $ 10 $ 11 $ 14 $ 110 $ 141 $ 151 $ 199 Integration and transaction-related costs 14 16 99 130 36 45 173 227 Charges associated with litigation matters — — — — (21) (27) 19 25 Charge for organizational efficiency plan — — — — — — 24 31 Contractual adjustment for a former client — — — — — — (66) (87) Total impact from special items $ 23 $ 26 $ 110 $ 144 $ 125 $ 159 $ 301 $ 395
Summarized Segment Financial Information	Summarized segment financial information was as follows: (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Three months ended June 30, 2021 Revenues from external customers $ 31,553 $ 9,689 $ 1,527 $ 52 $ — $ 42,821 Inter-segment revenues 1,034 595 — — (1,629) Net investment income 5 172 55 77 1 310 Total revenues 32,592 10,456 1,582 129 (1,628) 43,131 Net realized investment results from certain equity method investments — — (24) — — (24) Adjusted revenues $ 32,592 $ 10,456 $ 1,558 $ 129 $ (1,628) $ 43,107 Income (loss) before taxes $ 929 $ 1,060 $ 260 $ 19 $ (370) $ 1,898 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (6) — (5) — — (11) Net realized investment (gains) losses 2 (49) (30) (6) — (83) Amortization of acquired intangible assets 488 6 9 — — 503 Special items Debt extinguishment costs — — — — 10 10 Integration and transaction-related costs — — — — 16 16 Pre-tax adjusted income (loss) from operations $ 1,413 $ 1,017 $ 234 $ 13 $ (344) $ 2,333 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Three months ended June 30, 2020 Revenues from external customers $ 27,714 $ 8,684 $ 1,466 $ 1,178 $ — $ 39,042 Inter-segment revenues 885 504 — 6 (1,395) Net investment income 3 49 26 144 1 223 Total revenues 28,602 9,237 1,492 1,328 (1,394) 39,265 Net realized investment results from certain equity method investments — — (60) — — (60) Adjusted revenues $ 28,602 $ 9,237 $ 1,432 $ 1,328 $ (1,394) $ 39,205 Income (loss) before taxes $ 771 $ 1,543 $ 390 $ 129 $ (544) $ 2,289 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (3) — (5) — — (8) Net realized investment (gains) losses — (26) (73) 1 — (98) Amortization of acquired intangible assets 481 6 7 2 — 496 Special items Debt extinguishment costs — — — — 14 14 Integration and transaction-related costs — — — — 130 130 Pre-tax adjusted income (loss) from operations $ 1,249 $ 1,523 $ 319 $ 132 $ (400) $ 2,823 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Six Months Ended June 30, 2021 Revenues from external customers $ 60,972 $ 19,291 $ 3,026 $ 112 $ — $ 83,401 Inter-segment revenues 2,232 1,105 — — (3,337) Net investment income 8 422 114 156 1 701 Total revenues 63,212 20,818 3,140 268 (3,336) 84,102 Net realized investment results from certain equity method investments — — (10) — — (10) Adjusted revenues $ 63,212 $ 20,818 $ 3,130 $ 268 $ (3,336) $ 84,092 Income (loss) before taxes $ 1,678 $ 2,069 $ 486 $ 35 $ (857) $ 3,411 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) — (12) — — (23) Net realized investment (gains) losses (1) 4 (79) 3 2 — (70) Amortization of acquired intangible assets 965 14 19 — — 998 Special items Debt extinguishment costs — — — — 141 141 Integration and transaction-related costs — — — — 45 45 Charges associated with litigation matters — — — — (27) (27) Pre-tax adjusted income (loss) from operations $ 2,636 $ 2,004 $ 496 $ 37 $ (698) $ 4,475 (In millions) Evernorth U.S. Medical International Markets Other Operations Corporate and Eliminations Total Six Months Ended June 30, 2020 Revenues from external customers $ 53,970 $ 17,952 $ 2,886 $ 2,350 $ — $ 77,158 Inter-segment revenues 1,859 970 — 11 (2,840) Net investment income 28 175 66 306 1 576 Total revenues 55,857 19,097 2,952 2,667 (2,839) 77,734 Net realized investment results from certain equity method investments — — (50) — — (50) Special item related to contractual adjustment for a former client (87) — — — — (87) Adjusted revenues $ 55,770 $ 19,097 $ 2,902 $ 2,667 $ (2,839) $ 77,597 Income (loss) before taxes $ 1,465 $ 2,683 $ 624 $ 201 $ (1,287) $ 3,686 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (7) — (10) — — (17) Net realized investment (gains) losses (1) — 22 (27) 5 — — Amortization of acquired intangible assets 960 17 14 3 — 994 Special items Debt extinguishment costs — — — — 199 199 Integration and transaction-related costs — — — — 227 227 Charges associated with litigation matters — — — — 25 25 Charge for organizational efficiency plan — — — — 31 31 Contractual adjustment for a former client (87) — — — — (87) Pre-tax adjusted income (loss) from operations $ 2,331 $ 2,722 $ 601 $ 209 $ (805) $ 5,058
Revenue from External Customers	Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type for the three and six months ended June 30: Three Months Ended June 30, Six Months Ended June 30, (In millions) 2021 2020 2021 2020 Products (Pharmacy revenues) (ASC 606) Network revenues $ 15,414 $ 13,090 $ 29,593 $ 25,232 Home delivery and specialty revenues 13,014 12,183 25,472 23,897 Other 1,619 1,291 3,007 2,533 Total pharmacy revenues $ 30,047 $ 26,564 $ 58,072 $ 51,662 Insurance premiums (ASC 944) U.S. Medical premiums U.S. Commercial Health Insurance 3,578 3,090 7,101 6,551 Stop loss 1,194 1,152 2,388 2,313 Other 308 283 618 572 U.S. Government Medicare Advantage 2,116 1,904 4,208 3,785 Medicare Part D 410 420 860 882 Other 1,227 1,063 2,365 2,129 Total U.S. Medical premiums 8,833 7,912 17,540 16,232 International Markets premiums 1,442 1,344 2,892 2,719 Domestic disability, life and accident premiums — 1,124 — 2,240 Other premiums 48 26 105 55 Total premiums 10,323 10,406 20,537 21,246 Services (ASC 606) Fees 2,345 1,979 4,672 4,133 Other external revenues 106 93 120 117 Total services 2,451 2,072 4,792 4,250 Total revenues from external customers $ 42,821 $ 39,042 $ 83,401 $ 77,158

Description of Business (Detail

Description of Business (Details)	3 Months Ended
	Sep. 30, 2020position
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments renamed	2
Number of operating segments renamed	2

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Receivables [Abstract]
Noninsurance customer receivables	$ 6,620	$ 5,534
Pharmaceutical manufacturers receivable	6,123	4,676
Insurance customer receivables	2,429	1,789
Other receivables	290	192
Total	$ 15,462	$ 12,191

Accounts Receivable, Net - Narr

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Receivables [Abstract]
Allowance for receivables net current	$ 1,500	$ 1,200
Allowance for current expected credit losses on accounts receivable	$ 57	$ 65

Mergers, Acquisitions and Div_2

Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Millions	Apr. 19, 2021	Dec. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Business Acquisition [Line Items]
Goodwill		$ 44,648	$ 46,063		$ 46,063
Acquired intangible assets		35,179	35,007		35,007
Integration and transaction-related costs, pre-tax			16	$ 130	45	$ 227
Integration and transaction-related costs, after-tax			$ 14	$ 99	$ 36	$ 173
U.S Group Disability and Life Insurance | Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of business		6,200
Gain (loss) on sale of business, pre-tax		4,200
Gain (loss) on sale of business, after-tax		$ 3,200
MDLIVE, Inc.
Business Acquisition [Line Items]
Ownership interest acquired	97.00%
Ownership interest after acquisition	100.00%
Total purchase price	$ 2,028
Goodwill	1,437
MDLIVE, Inc. | Customer relationships
Business Acquisition [Line Items]
Acquired intangible assets	577
Amortization period					17 years
MDLIVE, Inc. | Evernorth
Business Acquisition [Line Items]
Goodwill	$ 1,300

Mergers, Acquisitions and Dis_2

Mergers, Acquisitions and Dispositions - Purchase Price Allocation (Details) - USD ($) $ in Millions	Jun. 30, 2021	Apr. 19, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill	$ 46,063		$ 44,648
MDLIVE, Inc.
Business Acquisition [Line Items]
Goodwill		$ 1,437
Acquired intangible assets		627
Tangible assets acquired net of liabilities assumed		19
Total consideration transferred		$ 2,083

Mergers, Acquisitions and Dis_3

Mergers, Acquisitions and Dispositions - Merger Consideration (Details) - MDLIVE, Inc. $ in Millions	Apr. 19, 2021USD ($)
Business Acquisition [Line Items]
Total consideration transferred	$ 2,083
Less: Fair value to Cigna's previously held equity interest	(55)
Total purchase price	$ 2,028

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Shareholders’ net income	$ 1,467	$ 1,754	$ 2,628	$ 2,935
Shares:
Weighted average (in shares)	341,479	367,396	344,845	368,918
Common stock equivalents (in shares)	3,450	3,301	3,589	3,750
Total shares (in shares)	344,929	370,697	348,434	372,668
EPS, basic (in dollars per share)	$ 4.30	$ 4.77	$ 7.62	$ 7.96
EPS, effect of dilution (in dollars per share)	(0.05)	(0.04)	(0.08)	(0.08)
EPS, diluted (in dollars per share)	$ 4.25	$ 4.73	$ 7.54	$ 7.88

Earnings Per Share - Outstandin

Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options (in shares)	1.5	4	1.5	4

Earnings Per Share - Shares of

Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares shares in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Earnings Per Share [Abstract]
Shares of common stock held in treasury (in shares)	52.2	35.5	20.8

Debt - Outstanding Amounts of D

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Short-term debt
Commercial paper	$ 1,512,000,000	$ 1,030,000,000
Other, including finance leases	20,000,000	18,000,000
Total short-term debt	1,532,000,000	3,374,000,000
Long-term debt
Other, including finance leases	31,000,000	36,000,000
Total long-term debt	31,606,000,000	29,545,000,000
$78 million, 6.37% Notes due 6/2021
Short-term debt
Current maturities	0	78,000,000
Long-term debt
Gross value		$ 78,000,000
Stated interest rate		6.37%
$1,000 million, Floating Rate Notes due 9/2021
Short-term debt
Current maturities	0	$ 999,000,000
Long-term debt
Gross value		1,000,000,000
$1,250 million, 3.4% Notes due 9/2021
Short-term debt
Current maturities	0	1,249,000,000
Long-term debt
Gross value		$ 1,250,000,000
Stated interest rate		3.40%
Notes due 2022 4% Interest
Long-term debt
Long-term debt	0	$ 276,000,000
Gross value		$ 277,000,000
Stated interest rate		4.00%
Notes Due 2022, 3.9% Interest
Long-term debt
Long-term debt	0	$ 972,000,000
Gross value		$ 973,000,000
Stated interest rate		3.90%
$500 million, 3.05% Notes due 2022
Long-term debt
Long-term debt	493,000,000	$ 490,000,000
Gross value	$ 500,000,000
Stated interest rate	3.05%
$17 million, 8.3% Notes due 2023
Long-term debt
Long-term debt	$ 17,000,000	17,000,000
Gross value	$ 17,000,000
Stated interest rate	8.30%
$63 million, 7.65% Notes due 2023
Long-term debt
Long-term debt	$ 63,000,000	63,000,000
Gross value	$ 63,000,000
Stated interest rate	7.65%
$700 million, Floating Rate Notes due 2023
Long-term debt
Long-term debt	$ 699,000,000	698,000,000
Gross value	700,000,000
$1,000 million, 3% Notes due 2023
Long-term debt
Long-term debt	980,000,000	975,000,000
Gross value	$ 1,000,000,000
Stated interest rate	3.00%
$1,187 million, 3.75% Notes due 2023
Long-term debt
Long-term debt	$ 1,184,000,000	2,181,000,000
Gross value	$ 1,187,000,000
Stated interest rate	3.75%
$500 million, 0.613% Notes due 2024
Long-term debt
Long-term debt	$ 498,000,000	0
Gross value	$ 500,000,000
Stated interest rate	0.613%
$1,000 million, 3.5% Notes due 2024
Long-term debt
Long-term debt	$ 980,000,000	977,000,000
Gross value	$ 1,000,000,000
Stated interest rate	3.50%
$900 million, 3.25% Notes due 2025
Long-term debt
Long-term debt	$ 896,000,000	896,000,000
Gross value	$ 900,000,000
Stated interest rate	3.25%
$2,200 million, 4.125% Notes due 2025
Long-term debt
Long-term debt	$ 2,192,000,000	2,191,000,000
Gross value	$ 2,200,000,000
Stated interest rate	4.125%
$1,500 million, 4.5% Notes due 2026
Long-term debt
Long-term debt	$ 1,504,000,000	1,505,000,000
Gross value	$ 1,500,000,000
Stated interest rate	4.50%
$800 million, 1.25% Notes due 2026
Long-term debt
Long-term debt	$ 796,000,000	0
Gross value	$ 800,000,000
Stated interest rate	1.25%
$1,500 million, 3.4% Notes due 2027
Long-term debt
Long-term debt	$ 1,416,000,000	1,410,000,000
Gross value	$ 1,500,000,000
Stated interest rate	3.40%
$259 million, 7.875% Debentures due 2027
Long-term debt
Long-term debt	$ 259,000,000	259,000,000
Gross value	$ 259,000,000
Stated interest rate	7.875%
$600 million, 3.05% Notes due 2027
Long-term debt
Long-term debt	$ 596,000,000	595,000,000
Gross value	$ 600,000,000
Stated interest rate	3.05%
$3,800 million, 4.375% Notes due 2028
Long-term debt
Long-term debt	$ 3,781,000,000	3,780,000,000
Gross value	$ 3,800,000,000
Stated interest rate	4.375%
$1,500 million, 2.4% Notes due 2030
Long-term debt
Long-term debt	$ 1,490,000,000	1,489,000,000
Gross value	$ 1,500,000,000
Stated interest rate	2.40%
$1,500 million, 2.375% Notes due 2031 (1)
Long-term debt
Long-term debt	$ 1,507,000,000	0
Gross value	$ 1,500,000,000
Stated interest rate	2.375%
$45 million, 8.3% Step Down Notes due 2033
Long-term debt
Long-term debt	$ 45,000,000	45,000,000
Gross value	$ 45,000,000
Stated interest rate	8.30%
$190 million, 6.15% Notes due 2036
Long-term debt
Long-term debt	$ 190,000,000	190,000,000
Gross value	$ 190,000,000
Stated interest rate	6.15%
$2,200 million, 4.8% Notes due 2038 (1)
Long-term debt
Long-term debt	$ 2,191,000,000	2,180,000,000
Gross value	$ 2,200,000,000
Stated interest rate	4.80%
$750 million, 3.2% Notes due 2040
Long-term debt
Long-term debt	$ 743,000,000	742,000,000
Gross value	$ 750,000,000
Stated interest rate	3.20%
$121 million, 5.875% Notes due 2041
Long-term debt
Long-term debt	$ 119,000,000	119,000,000
Gross value	$ 121,000,000
Stated interest rate	5.875%
$448 million, 6.125% Notes due 2041
Long-term debt
Long-term debt	$ 490,000,000	490,000,000
Gross value	$ 448,000,000
Stated interest rate	6.125%
$317 million, 5.375% Notes due 2042
Long-term debt
Long-term debt	$ 315,000,000	315,000,000
Gross value	$ 317,000,000
Stated interest rate	5.375%
$1,500 million, 4.8% Notes due 2046
Long-term debt
Long-term debt	$ 1,465,000,000	1,465,000,000
Gross value	$ 1,500,000,000
Stated interest rate	4.80%
$1,000 million, 3.875% Notes due 2047
Long-term debt
Long-term debt	$ 988,000,000	988,000,000
Gross value	$ 1,000,000,000
Stated interest rate	3.875%
$3,000 million, 4.9% Notes due 2048
Long-term debt
Long-term debt	$ 2,967,000,000	2,966,000,000
Gross value	$ 3,000,000,000
Stated interest rate	4.90%
$1,250 million, 3.4% Notes due 2050
Long-term debt
Long-term debt	$ 1,235,000,000	1,235,000,000
Gross value	$ 1,250,000,000
Stated interest rate	3.40%
$1,500 million , 3.4% Notes due 2051
Long-term debt
Long-term debt	$ 1,476,000,000	$ 0
Gross value	$ 1,500,000,000
Stated interest rate	3.40%

Debt - Summary of Debt Issuance

Debt - Summary of Debt Issuances (Details) - USD ($)	Mar. 03, 2021	Jun. 30, 2021
Senior Notes
Debt Instrument [Line Items]
Principal	$ 4,300,000,000
$500 million, 0.613% Notes due 2024
Debt Instrument [Line Items]
Interest rate		0.613%
$500 million, 0.613% Notes due 2024 | Senior Notes
Debt Instrument [Line Items]
Principal	$ 500,000,000
Interest rate	0.613%
Net proceeds	$ 499,000,000
$800 million, 1.25% Notes due 2026
Debt Instrument [Line Items]
Interest rate		1.25%
$800 million, 1.25% Notes due 2026 | Senior Notes
Debt Instrument [Line Items]
Principal	$ 800,000,000
Interest rate	1.25%
Net proceeds	$ 797,000,000
$1,500 million, 2.375% Notes due 2031 (1)
Debt Instrument [Line Items]
Interest rate		2.375%
$1,500 million, 2.375% Notes due 2031 (1) | Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Interest rate	2.375%
Net proceeds	$ 1,492,000,000
$1,500 million , 3.4% Notes due 2051
Debt Instrument [Line Items]
Interest rate		3.40%
$1,500 million , 3.4% Notes due 2051 | Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Interest rate	3.40%
Net proceeds	$ 1,479,000,000

Debt - Narrative (Details)

Debt - Narrative (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2021USD ($)bank	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jul. 30, 2021USD ($)	Mar. 03, 2021USD ($)
Debt Instrument [Line Items]
Aggregate principal amount of outstanding debt securities redeemed		$ 4,500,000,000		$ 4,500,000,000
Loss on repurchase of debt, pre-tax		10,000,000	$ 14,000,000	141,000,000	$ 199,000,000
Loss on repurchase of debt, after-tax		110,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		4,250,000,000		$ 4,250,000,000
Commercial Paper | Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 5,000,000,000
Five-year Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Credit agreement term				5 years
364-day Revolving Credit Agreement, Maturing October 2021
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	364 days
Revolving Credit and Letter of Credit Facility Maturing April 2026, Revolving Credit and Letter of Credit Facility Maturing April 2024, and 364 Day Revolving Credit Agreement Maturing April 2022
Debt Instrument [Line Items]
Aggregate amount of options to increase commitments	$ 1,500,000,000
Outstanding balances		$ 0		$ 0
Five-year Revolving Credit Agreement, Maturing April 2026
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 3,000,000,000
Number of participating banks | bank	23
Amount by which credit facilty term length can be increased	1 year
Credit agreement term	5 years
Leverage ratio covenant	60.00%
Five-year Revolving Credit Agreement, Maturing April 2026 | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Three-year Revolving Credit Agreement, Maturing April 2024
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Number of participating banks | bank	23
Amount by which credit facilty term length can be increased	1 year
Credit agreement term	3 years
Leverage ratio covenant	60.00%
364-day Revolving Credit Agreement, Maturing April 2022
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Number of participating banks | bank	23
Credit agreement term	364 days
Term of borrowing after exercising the "term out" option	1 year
Leverage ratio covenant	60.00%
Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount							$ 4,300,000,000

Insurance and Contractholder _3

Insurance and Contractholder Liabilities - Summary of Insurance and Contractholder Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Current
Contractholder deposit funds	$ 357	$ 350
Future policy benefits	314	327
Unearned premiums	511	485
Total insurance and contractholder liabilities	5,850	5,308
Non-current
Contractholder deposit funds	6,765	6,823
Future policy benefits	9,217	9,317
Unearned premiums	401	394
Total insurance and contractholder liabilities	16,665	16,844
Total
Contractholder deposit funds	7,122	7,173
Future policy benefits	9,531	9,644
Unearned premiums	912	879
Contractholder deposit funds			$ 7,689
Future policy benefits			9,945
Unearned premiums			930
Total			27,673
Insurance and contractholder liabilities classified as held for sale			(6,549)
Total insurance and contractholder liabilities	22,515	22,152	21,124
Unpaid claims classified as liabilities of business held for sale			5,100
Contractholder deposit funds classified as liabilities of business held for sale			758
Future policy benefits classified as liabilities of business held for sale			644
Integrated Medical
Current
Unpaid claims and claim expenses	3,726	3,166
Non-current
Unpaid claims and claim expenses	19	18
Total
Unpaid claims and claim expenses	3,745	3,184
Unpaid claims and claim expenses			2,959	$ 2,892
Other segments
Current
Unpaid claims and claim expenses	942	980
Non-current
Unpaid claims and claim expenses	263	292
Total
Unpaid claims and claim expenses	$ 1,205	$ 1,272
Unpaid claims and claim expenses			$ 6,150

Insurance and Contractholder _4

Insurance and Contractholder Liabilities - Narrative (Details) - USD ($) $ in Billions	Jun. 30, 2021	Jun. 30, 2020
Integrated Medical
Insurance and Contractholder Liabilities [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process	$ 3.4	$ 2.7

Insurance and Contractholder _5

Insurance and Contractholder Liabilities - U.S. Medical - Activity (Details) - Integrated Medical - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	$ 3,184
Beginning balance, including disposal groups		$ 2,892
Less: Reinsurance and other amounts recoverable	224
Less: Reinsurance and other amounts recoverable, including disposal groups		303
Beginning balance, net	2,960
Beginning balance, net, including disposal groups		2,589
Incurred costs related to:
Current year	14,796	12,212
Prior years	(181)	(130)
Total incurred	14,615	12,082
Paid costs related to:
Current year	11,451	9,585
Prior years	2,572	2,284
Total paid	14,023	11,869
Ending balance, net	3,552
Ending balance, net, including disposal groups		2,802
Add: Reinsurance and other amounts recoverable	193
Add: Reinsurance and other amounts recoverable, including disposal groups		157
Ending balance	$ 3,745
Ending balance, including disposal groups		$ 2,959

Insurance and Contractholder _6

Insurance and Contractholder Liabilities - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Integrated Medical - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 181	$ 130
Favorable (unfavorable) variance, percentage	0.70%	0.50%
Actual completion factors
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 55	$ 50
Favorable (unfavorable) variance, percentage	0.20%	0.20%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 126	$ 80
Favorable (unfavorable) variance, percentage	0.50%	0.30%

Insurance and Contractholder _7

Insurance and Contractholder Liabilities - Liability Details for Unpaid Claims and Claim Expenses (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Group Disability And Other And International Markets [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 1,205
Unpaid claims and claim expenses			$ 6,150
Total Other Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	284
Unpaid claims and claim expenses			5,325
Group Disability and Life
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	0
Unpaid claims and claim expenses			5,165
Other Operations
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	284
Unpaid claims and claim expenses			160
International Markets [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Unpaid claims and claim expenses	$ 921	$ 963
Unpaid claims and claim expenses			$ 825

Insurance and Contractholder _8

Insurance and Contractholder Liabilities - Activity in Liabilities for Unpaid Claims and Claim Expenses (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Intenational Markets and Group Disability and Life
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance, including disposal groups		$ 5,816
Less: Reinsurance and other amounts recoverable, including disposal groups		184
Beginning balance, net, including disposal groups		5,632
Incurred claims related to:
Current year		2,829
Prior years:
Interest accretion		81
All other incurred		(8)
Total incurred		2,902
Paid costs related to:
Current year		1,357
Prior years		1,353
Total paid		2,710
Foreign currency		(14)
Ending balance, net, including disposal groups		5,810
Add: Reinsurance and other amounts recoverable, including disposal groups		180
Ending balance, including disposal groups		5,990
International Markets [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Beginning balance	$ 963
Less: Reinsurance and other amounts recoverable	59
Beginning balance, net	904
Incurred claims related to:
Current year	1,421
Prior years:
Interest accretion	0
All other incurred	(51)
Total incurred	1,370
Paid costs related to:
Current year	922
Prior years	467
Total paid	1,389
Foreign currency	(21)
Ending balance, net	864
Add: Reinsurance and other amounts recoverable	57
Ending balance, including disposal groups		$ 825
Ending balance	$ 921

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)reinsurer	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)reinsurer
GMIB
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100.00%		100.00%
Annuitization election period	30 days
GMIB liabilities	$ 604		$ 729
Number of external reinsurers | reinsurer	3		3
Amounts included in shareholders net income for GMIB assets
Amounts included in shareholders net income for GMIB liabilities
Variable Annuity | Berkshire
Effects of Reinsurance [Line Items]
Percent of future claim payments reinsured	100.00%
Remaining overall limit under reinsurance agreement	$ 3,200
Other Current Assets
Effects of Reinsurance [Line Items]
Reinsurance recoverables	$ 227		$ 217

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables by Range of External Credit Rating and Collateral Level (Details) $ in Millions	Jun. 30, 2021USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 5,372
Allowance for uncollectible reinsurance	(31)
Total reinsurance recoverables	5,341
Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,205
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,856
No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	311
Ongoing Operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables	383
Ongoing Operations | Upper-medium grade and higher
Ceded Credit Risk [Line Items]
Reinsurance recoverables	182
Ongoing Operations | Lower-medium grade
Ceded Credit Risk [Line Items]
Reinsurance recoverables	64
Ongoing Operations | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	137
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	93
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Lower-medium grade
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	93
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Lower-medium grade
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	290
Ongoing Operations | No collateral | Upper-medium grade and higher
Ceded Credit Risk [Line Items]
Reinsurance recoverables	182
Ongoing Operations | No collateral | Lower-medium grade
Ceded Credit Risk [Line Items]
Reinsurance recoverables	64
Ongoing Operations | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	44
Acquisition, disposition or runoff activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables	4,989
Acquisition, disposition or runoff activities | Upper-medium grade and higher | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,987
Acquisition, disposition or runoff activities | Upper-medium grade and higher | Berkshire
Ceded Credit Risk [Line Items]
Reinsurance recoverables	674
Acquisition, disposition or runoff activities | Upper-medium grade and higher | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	594
Acquisition, disposition or runoff activities | Upper-medium grade and higher | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	457
Acquisition, disposition or runoff activities | Upper-medium grade and higher | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	261
Acquisition, disposition or runoff activities | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	16
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	1,112
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher | Berkshire
Ceded Credit Risk [Line Items]
Reinsurance recoverables	292
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	594
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Upper-medium grade and higher | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	226
Acquisition, disposition or runoff activities | Fair value of collateral contractually required to meet or exceed carrying value of recoverable | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,856
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,987
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher | Berkshire
Ceded Credit Risk [Line Items]
Reinsurance recoverables	382
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	457
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Upper-medium grade and higher | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	17
Acquisition, disposition or runoff activities | Collateral provisions exist that may mitigate risk of credit loss | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	13
Acquisition, disposition or runoff activities | No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	21
Acquisition, disposition or runoff activities | No collateral | Upper-medium grade and higher | Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | No collateral | Upper-medium grade and higher | Berkshire
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | No collateral | Upper-medium grade and higher | Prudential Retirement Insurance and Annuity
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | No collateral | Upper-medium grade and higher | Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or runoff activities | No collateral | Upper-medium grade and higher | Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	18
Acquisition, disposition or runoff activities | No collateral | Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 3

Reinsurance - Effects of Reinsu

Reinsurance - Effects of Reinsurance 10-Q (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Reinsurance Disclosures [Abstract]
Total ceded premiums	$ 134	$ 117	$ 284	$ 245
Total reinsurance recoveries	$ 133	$ 102	$ 281	$ 280

Reinsurance - Account Value, Ne

Reinsurance - Account Value, Net Amount at Risk and Contractholders for GMDB Business (Details) - Variable Annuity - GMDB contractholder in Thousands, $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)contractholder	Dec. 31, 2019contractholder	Dec. 31, 2020USD ($)
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 9,835		$ 9,523
Net amount at risk	$ 1,450		$ 1,570
Number of contractholders (estimated) | contractholder	175	185

Reinsurance - GMIB Reinsurers (

Reinsurance - GMIB Reinsurers (Details) - GMIB - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 631	$ 758
Berkshire
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 295	353
Berkshire | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100.00%
Sun Life Assurance Company of Canada
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 177	215
Liberty Re (Bermuda) Ltd.
Ceded Credit Risk [Line Items]
GMIB recoverables	$ 159	$ 190
Liberty Re (Bermuda) Ltd. | Secured | GMIB Assets | Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100.00%

Investments - Investments by Ca

Investments - Investments by Category (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Schedule of Investments [Line Items]
Current	$ 1,305	$ 1,331
Long-term	23,622	23,262
Total	24,927	24,593
Debt securities
Schedule of Investments [Line Items]
Current	904	959
Long-term	17,258	17,172
Total	18,162	18,131
Equity securities
Schedule of Investments [Line Items]
Current	0	0
Long-term	530	501
Total	530	501
Commercial mortgage loans
Schedule of Investments [Line Items]
Current	52	13
Long-term	1,399	1,406
Total	1,451	1,419
Policy loans
Schedule of Investments [Line Items]
Current	0	0
Long-term	1,341	1,351
Total	1,341	1,351
Other long-term investments
Schedule of Investments [Line Items]
Current	0	0
Long-term	3,094	2,832
Total	3,094	2,832
Short-term investments
Schedule of Investments [Line Items]
Current	349	359
Long-term	0	0
Total	$ 349	$ 359

Investments - Debt Securities b

Investments - Debt Securities by Contractual Maturity Periods (Details) $ in Millions	Jun. 30, 2021USD ($)
Amortized Cost
Due in one year or less	$ 939
Due after one year through five years	5,431
Due after five years through ten years	5,873
Due after ten years	3,947
Mortgage and other asset-backed securities	472
Total	16,662
Fair Value
Due in one year or less	945
Due after one year through five years	5,682
Due after five years through ten years	6,297
Due after ten years	4,761
Mortgage and other asset-backed securities	477
Total	$ 18,162

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Schedule of Investments [Line Items]
Realized gains (losses) on investments still held at the reporting date
Fair value of collateral posted
Gain (loss) recognized in the income statement
Gain (loss) recognized in other comprehensive income
Gains (losses) reclassified from other comprehensive income into shareholders' net income
Amounts excluded from assessment of hedge effectiveness
Amount of impairments or value changes resulting from observable price changes on equity securities with no readily available fair value still held
Commercial Portfolio Segment | Real Estate Loan
Schedule of Investments [Line Items]
Allowance for credit losses on financing receivables		$ 6		$ 6

Investments - Gross Unrealized

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 16,662	$ 16,220
Allowance for Credit Loss	(36)	(26)
Unrealized Appreciation	1,618	1,990
Unrealized Depreciation	(82)	(53)
Fair Value	18,162	18,131
Run-Off Settlement Annuity Business
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,307	2,282
Allowance for Credit Loss	(4)	(5)
Unrealized Appreciation	727	838
Unrealized Depreciation	(7)	(3)
Fair Value	3,023	3,112
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	288	334
Allowance for Credit Loss	0	0
Unrealized Appreciation	107	122
Unrealized Depreciation	0	0
Fair Value	395	456
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	149	150
Allowance for Credit Loss	0	0
Unrealized Appreciation	18	17
Unrealized Depreciation	0	0
Fair Value	167	167
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	2,284	2,201
Allowance for Credit Loss	0	0
Unrealized Appreciation	238	318
Unrealized Depreciation	(22)	(8)
Fair Value	2,500	2,511
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	13,469	13,108
Allowance for Credit Loss	(24)	(19)
Unrealized Appreciation	1,234	1,506
Unrealized Depreciation	(56)	(33)
Fair Value	14,623	14,562
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	472	427
Allowance for Credit Loss	(12)	(7)
Unrealized Appreciation	21	27
Unrealized Depreciation	(4)	(12)
Fair Value	$ 477	$ 435

Investments - Summary of Debt S

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Jun. 30, 2021USD ($)position	Dec. 31, 2020USD ($)position
More than one year
Fair Value	$ 2,817	$ 1,515
Amortized Cost	2,899	1,568
Unrealized Depreciation	$ (82)	$ (53)
Number of Issues | position	1,236	571
Investment grade
One year or less
Fair Value	$ 2,178	$ 1,026
Amortized Cost	2,239	1,045
Unrealized Depreciation	$ (61)	$ (19)
Number of Issues | position	680	300
More than one year
Fair Value	$ 53	$ 18
Amortized Cost	55	18
Unrealized Depreciation	$ (2)	$ 0
Number of Issues | position	12	6
Below investment grade
One year or less
Fair Value	$ 439	$ 381
Amortized Cost	451	405
Unrealized Depreciation	$ (12)	$ (24)
Number of Issues | position	512	232
More than one year
Fair Value	$ 147	$ 90
Amortized Cost	154	100
Unrealized Depreciation	$ (7)	$ (10)
Number of Issues | position	32	33

Investments - Equity Security I

Investments - Equity Security Investments (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Cost
Equity securities with readily determinable fair values	$ 203	$ 180
Equity securities with no readily determinable fair value	232	225
Hybrid equity securities	58	58
Total	493	463
Carrying Value
Equity securities with readily determinable fair values	208	202
Equity securities with no readily determinable fair value	283	255
Hybrid equity securities	39	44
Total	$ 530	$ 501

Investments - Summary of the Cr

Investments - Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Schedule of Investments [Line Items]
Allowance for credit losses	$ (6)	$ (6)
Total	$ 1,451	$ 1,419
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.93	2.08
Average Loan-to-Value Ratio	60.00%	61.00%
Below 60%
Schedule of Investments [Line Items]
Carrying Value	$ 592	$ 533
Below 60% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.18	2.28
60% to 79%
Schedule of Investments [Line Items]
Carrying Value	$ 735	$ 751
60% to 79% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.80	2.08
80% to 100%
Schedule of Investments [Line Items]
Carrying Value	$ 130	$ 141
80% to 100% | Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.47	1.33

Investments - Carrying Values o

Investments - Carrying Values of Other Long-Term Investments (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Schedule of Investments [Line Items]
Other long-term investments	$ 3,094	$ 2,832
Real estate investments
Schedule of Investments [Line Items]
Other long-term investments	1,078	951
Securities partnerships
Schedule of Investments [Line Items]
Other long-term investments	1,853	1,737
Other
Schedule of Investments [Line Items]
Other long-term investments	$ 163	$ 144

Investments - Summary of Deriva

Investments - Summary of Derivative Instruments Held (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Designated as Hedging Instrument | Fair Value Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	$ 1,040	$ 925
Designated as Hedging Instrument | Fair Value Hedging | Interest rate swap contracts
Derivative [Line Items]
Notional Value	750	0
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency swap contracts
Derivative [Line Items]
Notional Value	526	526
Designated as Hedging Instrument | Net Investment Hedging | Foreign currency forward contracts
Derivative [Line Items]
Notional Value	686	636
Not Designated as Hedging Instrument, Economic Hedge | Foreign currency forward contracts
Derivative [Line Items]
Notional Value	643	538
Not Designated as Hedging Instrument, Economic Hedge | Average rate option contracts
Derivative [Line Items]
Notional Value	$ 269	$ 0

Investments - Realized Gains an

Investments - Realized Gains and Losses on Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Investments [Abstract]
Net realized investment gains (losses), excluding credit loss expense and asset write-downs	$ 60	$ 33	$ 70	$ 9
Credit loss (expense) recoveries	(1)	6	(10)	(49)
Other investment asset write-downs	0	(1)	0	(10)
Net realized investment gains (losses), before income taxes	$ 59	$ 38	$ 60	$ (50)

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Financial assets at fair value:
Debt Securities	$ 18,162
Recurring
Financial assets at fair value:
Debt Securities	18,162	$ 18,131
Equity securities	247	246
Short-term investments	348	325
Recurring | Other Derivatives
Financial assets at fair value:
Derivative assets	72	72
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	45	108
Recurring | Other Derivatives | Short-term investments
Financial assets at fair value:
Derivative assets	1
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	155	207
Equity securities	50	50
Short-term investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring | Other Derivatives
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	17,184	17,101
Equity securities	166	165
Short-term investments	348	325
Significant Other Observable Inputs (Level 2) | Recurring | Other Derivatives
Financial assets at fair value:
Derivative assets	72	72
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	45	108
Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	823	823
Equity securities	31	31
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) | Recurring | Other Derivatives
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Federal government and agency | Recurring
Financial assets at fair value:
Debt Securities	395	456
Federal government and agency | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	155	207
Federal government and agency | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	240	249
Federal government and agency | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government | Recurring
Financial assets at fair value:
Debt Securities	167	167
State and local government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	167	167
State and local government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government | Recurring
Financial assets at fair value:
Debt Securities	2,500	2,511
Foreign government | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	2,487	2,498
Foreign government | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	13	13
Corporate | Recurring
Financial assets at fair value:
Debt Securities	14,623	14,562
Corporate | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Corporate | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	13,956	13,878
Corporate | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	667	684
Mortgage and other asset-backed | Recurring
Financial assets at fair value:
Debt Securities	477	435
Mortgage and other asset-backed | Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring
Financial assets at fair value:
Debt Securities	0	0
Mortgage and other asset-backed | Significant Other Observable Inputs (Level 2) | Recurring
Financial assets at fair value:
Debt Securities	334	309
Mortgage and other asset-backed | Significant Unobservable Inputs (Level 3) | Recurring
Financial assets at fair value:
Debt Securities	$ 143	$ 126

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Realized investment losses on assets measured at fair value under certain conditions, after-tax
Realized investment gains on equity securities with no readily determinable fair value
Maximum
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets measured at fair value under certain conditions as a percent of total investments	1.00%	1.00%	1.00%	1.00%
Separate Account Assets
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), , including transfers in and out of Level 3
Separate accounts assets classified in Level 3, including disposal groups, period increase (decrease), including transfers in and out of Level 3
Separate Account Assets | Recurring | Securities partnerships
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected liquidation period after inception			10 years

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 823	$ 823
Debt securities | Securities Not Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	0	1
Corporate and government debt securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 680	$ 696
Corporate and government debt securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Corporate and government debt securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.1720	0.1370
Corporate and government debt securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0510	0.0470
Mortgage and other asset-backed securities | Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 143	$ 126
Mortgage and other asset-backed securities | Securities Priced by the Company | Minimum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Mortgage and other asset-backed securities | Securities Priced by the Company | Maximum | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0390	0.0380
Mortgage and other asset-backed securities | Securities Priced by the Company | Weighted Average | Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0090	0.0080

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Transfers into/(out of) Level 3
Change in unrealized gains or losses included in Other comprehensive income for assets held at the end of the reporting period	$ 7	$ 12	$ (9)	$ (54)
Debt and Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	903		854
Balance		766		555
Total gains (losses) included in shareholders’ net income	(1)	17	(11)	5
Gains (losses) included in other comprehensive income	7	12	(9)	(59)
Gains (losses) required to adjust future policy benefits for settlement annuities	1	7	(7)	(3)
Purchases, sales and settlements
Purchases	42	2	71	64
Sales	0	0	0	(12)
Settlements	(9)	(5)	(25)	(7)
Total purchases, sales and settlements	33	(3)	46	45
Transfers into/(out of) Level 3
Transfers into Level 3	37	179	123	527
Transfers out of Level 3	(126)	(118)	(142)	(210)
Total transfers into/(out of) Level 3	(89)	61	(19)	317
Balance	854		854
Balance		860		860
Total gains (losses) included in Shareholders’ net income attributable to instruments held at the reporting date	$ (1)	$ 16	$ (12)	$ (1)

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 518	$ 523
Non-guaranteed separate accounts	7,978	7,880
Subtotal	8,496	8,403
Non-guaranteed separate accounts priced at NAV as a practical expedient	765	683
Separate account assets per Consolidated Balance Sheets	9,261	9,086
Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	4,400	4,200
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	231	226
Non-guaranteed separate accounts	2,013	1,925
Subtotal	2,244	2,151
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	287	297
Non-guaranteed separate accounts	5,592	5,600
Subtotal	5,879	5,897
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0	0
Non-guaranteed separate accounts	373	355
Subtotal	373	355
Significant Unobservable Inputs (Level 3) | Pension Plan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 300	$ 300

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information on Separate Account Assets Priced at NAV (Details) - Separate Account Assets - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 293
Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	765	$ 683
Securities partnerships
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	270
Securities partnerships | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	483	463
Real estate funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 23
Real estate funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Real estate funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Real estate funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 278	215
Hedge funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Hedge funds | Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Hedge funds | Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Hedge funds | Recurring | NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 4	$ 5

Fair Value Measurements - Fai_3

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Fair Value | Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 36,076	$ 37,676
Fair Value | Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,494	1,456
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,451	1,419
Long-term debt, including current maturities, excluding finance leases	$ 31,575	$ 31,835

Variable Interest Entities (Det

Variable Interest Entities (Details) - entity	Jun. 30, 2021	Dec. 31, 2020
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 48,155	$ 45,086	$ 50,328	$ 45,344
Other comprehensive income (loss), net of tax	153	737	(221)	147
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(1)	(2)	(5)	(6)
Shareholders other comprehensive income (loss), net of tax	154	739	(216)	153
Balance	48,716	47,371	48,716	47,371
Securities and Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	627	547	900	975
Other comprehensive income (loss) before reclassifications, before tax	170	920	(172)	340
Other comprehensive income (loss) before reclassifications, tax	(40)	(196)	25	(69)
Other comprehensive income (loss) before reclassifications, after-tax	130	724	(147)	271
Reclassification adjustment, tax	3	4	2	(3)
Net amounts reclassified from AOCI to net income	(8)	(15)	(4)	10
Shareholders other comprehensive income (loss), net of tax	122	709	(151)	281
Balance	749	1,256	749	1,256
Reclassification adjustment for (gains) losses included in Shareholders' net income (Net realized investment (gains) losses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	(11)	(19)	(6)	13
Translation of foreign currencies
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications, before tax, including temporary equity	16	65	(98)	(95)
Other comprehensive income (loss) before reclassifications, tax, including temporary equity	0	5	(5)	(10)
Other comprehensive income (loss), net of tax	16	70	(103)	(105)
Translation of foreign currencies attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Less: Net translation gain (loss) on foreign currencies attributable to noncontrolling interests	(1)	(2)	(5)	(6)
Translation of foreign currencies attributable to parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(130)	(446)	(15)	(275)
Shareholders other comprehensive income (loss), net of tax	17	72	(98)	(99)
Balance	(113)	(374)	(113)	(374)
Postretirement benefits liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(1,728)	(1,628)	(1,746)	(1,641)
Other comprehensive income (loss) before reclassifications, before tax	0	(73)	0	(73)
Other comprehensive income (loss) before reclassifications, tax	0	17	0	17
Other comprehensive income (loss) before reclassifications, after-tax	0	(56)	0	(56)
Reclassification adjustment, tax	(5)	(4)	(10)	(9)
Net amounts reclassified from AOCI to net income	15	14	33	27
Shareholders other comprehensive income (loss), net of tax	15	(42)	33	(29)
Balance	(1,713)	(1,670)	(1,713)	(1,670)
Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	19	18	39	36
Reclassification adjustment for settlement (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax	$ 1	$ 0	$ 4	$ 0

Leases - Operating and Finance

Leases - Operating and Finance Lease Right of Use ("ROU") Assets and Lease Liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2021	Dec. 31, 2020
Operating leases:
Operating lease ROU assets	$ 508	$ 552
Accrued expenses and other liabilities	149	152
Other non-current liabilities	449	491
Total operating lease liabilities	598	643
Finance leases:
Property and equipment, gross	89	98
Accumulated depreciation	(40)	(46)
Property and equipment, net	49	52
Short-term debt	20	18
Long-term debt	31	36
Total finance lease liabilities	$ 51	$ 54
Balance sheet location of current operating lease liabilities
Balance sheet location of non-current operating lease liabilities	Other non-current liabilities	Other non-current liabilities
Balance sheet location of non-current finance lease assets	Property and equipment	Property and equipment
Balance sheet location of current finance lease liabilities	Short-term debt	Short-term debt
Balance sheet location of non-current finance lease liabilities	Long-term debt	Long-term debt

Income Taxes - 10-Q Narrative (

Income Taxes - 10-Q Narrative (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Consolidated effective tax rate	22.40%	20.00%

Contingencies and Other Matte_2

Contingencies and Other Matters (Details)	Apr. 19, 2016claim	Sep. 30, 2020USD ($)	Mar. 31, 2016USD ($)	Jun. 30, 2021USD ($)	Apr. 30, 2020USD ($)	Feb. 28, 2017USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Provision for loss contingency
Litigation Matters and Regulatory Matters
Commitments And Contingencies [Line Items]
Reserves for litigation matters, pre-tax
CSR Litigation with the Federal Government | Pending Litigation
Commitments And Contingencies [Line Items]
Damages sought by the complaint					$ 315,000,000
Express Scripts Litigation with Anthem | Pending Litigation
Commitments And Contingencies [Line Items]
Number of counts dismissed | claim	2
Number of counts | claim	6
Express Scripts Litigation with Anthem | Pending Litigation | Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Anthem			$ 13,000,000,000
Express Scripts Litigation with Anthem | Pending Litigation | Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Anthem			1,800,000,000
Express Scripts Litigation with Anthem | Pending Litigation | Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Anthem			$ 150,000,000
Collectibility of Risk Corridor Payments | CSR Litigation with the Federal Government | Pending Litigation
Commitments And Contingencies [Line Items]
Damages sought by the complaint					120,000,000
Proceeds related to legal claim		$ 120,000,000
Collectibility of CSRs | CSR Litigation with the Federal Government | Pending Litigation
Commitments And Contingencies [Line Items]
Damages sought by the complaint					$ 195,000,000
Positive Outcome of Litigation | Cigna Litigation with Anthem | Pending Litigation
Commitments And Contingencies [Line Items]
Reverse termination fee receivable						$ 1,850,000,000
Certain other guarantees, indemnification obligations in connection with acquisition and disposition transactions
Commitments And Contingencies [Line Items]
Liability for guarantees				0
Retiree and Life Insurance Benefits | Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure				450,000,000
Assets maintained by employers (minimum)				450,000,000
Liability for guarantees				$ 0

Segment Information - Summary o

Segment Information - Summary of Special Items (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
After-tax
Debt extinguishment costs	$ 9	$ 11	$ 110	$ 151
Integration and transaction-related costs (Selling, general and administrative expenses)	14	99	36	173
Charges associated with litigation matters (Selling, general and administrative expenses)	0	0	(21)	19
Charge for organizational efficiency plan (Selling, general and administrative expenses)	0	0	0	24
Contractual adjustment for a former client (Pharmacy revenues)	0	0	0	(66)
Total impact from special items	23	110	125	301
Before-tax
Debt extinguishment costs	10	14	141	199
Integration and transaction-related costs (Selling, general and administrative expenses)	16	130	45	227
Charges associated with litigation matters (Selling, general and administrative expenses)	0	0	(27)	25
Charge for organizational efficiency plan (Selling, general and administrative expenses)	0	0	0	31
Contractual adjustment for a former client (Pharmacy revenues)	0	0	0	(87)
Total impact from special items	$ 26	$ 144	$ 159	$ 395

Segment Information - Summarize

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Segment Reporting Information [Line Items]
Revenues from customers	$ 42,821	$ 39,042	$ 83,401	$ 77,158
Net investment income	310	223	701	576
TOTAL REVENUES	43,131	39,265	84,102	77,734
Net realized investment results from certain equity method investments	(24)	(60)	(10)	(50)
Special item related to contractual adjustment for a former client				(87)
Adjusted revenues	43,107	39,205	84,092	77,597
Depreciation and amortization			1,446	1,387
Income before income taxes	1,898	2,289	3,411	3,686
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(11)	(8)	(23)	(17)
Net realized investment (gains) losses	(83)	(98)	(70)	0
Amortization of acquired intangible assets	503	496	998	994
Special items
Debt extinguishment costs	10	14	141	199
Integration and transaction-related costs	16	130	45	227
Charges associated with litigation matters	0	0	(27)	25
Charge for organizational efficiency plan	0	0	0	31
Contractual adjustment for a former client	0	0	0	(87)
Pre-tax adjusted income (loss) from operations	2,333	2,823	4,475	5,058
Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	31,553	27,714	60,972	53,970
Integrated Medical
Segment Reporting Information [Line Items]
Revenues from customers	9,689	8,684	19,291	17,952
International Markets [Member]
Segment Reporting Information [Line Items]
Revenues from customers	1,527	1,466	3,026	2,886
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	52	1,178	112	2,350
Operating Segments | Evernorth
Segment Reporting Information [Line Items]
Net investment income	5	3	8	28
TOTAL REVENUES	32,592	28,602	63,212	55,857
Net realized investment results from certain equity method investments	0	0	0	0
Special item related to contractual adjustment for a former client				(87)
Adjusted revenues	32,592	28,602	63,212	55,770
Income before income taxes	929	771	1,678	1,465
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(6)	(3)	(11)	(7)
Net realized investment (gains) losses	2	0	4	0
Amortization of acquired intangible assets	488	481	965	960
Special items
Debt extinguishment costs	0	0	0	0
Integration and transaction-related costs	0	0	0	0
Charges associated with litigation matters			0	0
Charge for organizational efficiency plan				0
Contractual adjustment for a former client				(87)
Pre-tax adjusted income (loss) from operations	1,413	1,249	2,636	2,331
Operating Segments | Integrated Medical
Segment Reporting Information [Line Items]
Net investment income	172	49	422	175
TOTAL REVENUES	10,456	9,237	20,818	19,097
Net realized investment results from certain equity method investments	0	0	0	0
Special item related to contractual adjustment for a former client				0
Adjusted revenues	10,456	9,237	20,818	19,097
Income before income taxes	1,060	1,543	2,069	2,683
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0	0	0	0
Net realized investment (gains) losses	(49)	(26)	(79)	22
Amortization of acquired intangible assets	6	6	14	17
Special items
Debt extinguishment costs	0	0	0	0
Integration and transaction-related costs	0	0	0	0
Charges associated with litigation matters			0	0
Charge for organizational efficiency plan				0
Contractual adjustment for a former client				0
Pre-tax adjusted income (loss) from operations	1,017	1,523	2,004	2,722
Operating Segments | International Markets [Member]
Segment Reporting Information [Line Items]
Net investment income	55	26	114	66
TOTAL REVENUES	1,582	1,492	3,140	2,952
Net realized investment results from certain equity method investments	(24)	(60)	(10)	(50)
Special item related to contractual adjustment for a former client				0
Adjusted revenues	1,558	1,432	3,130	2,902
Income before income taxes	260	390	486	624
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(5)	(5)	(12)	(10)
Net realized investment (gains) losses	(30)	(73)	3	(27)
Amortization of acquired intangible assets	9	7	19	14
Special items
Debt extinguishment costs	0	0	0	0
Integration and transaction-related costs	0	0	0	0
Charges associated with litigation matters			0	0
Charge for organizational efficiency plan				0
Contractual adjustment for a former client				0
Pre-tax adjusted income (loss) from operations	234	319	496	601
Operating Segments | Other Operations
Segment Reporting Information [Line Items]
Net investment income	77	144	156	306
TOTAL REVENUES	129	1,328	268	2,667
Net realized investment results from certain equity method investments	0	0	0	0
Special item related to contractual adjustment for a former client				0
Adjusted revenues	129	1,328	268	2,667
Income before income taxes	19	129	35	201
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0	0	0	0
Net realized investment (gains) losses	(6)	1	2	5
Amortization of acquired intangible assets	0	2	0	3
Special items
Debt extinguishment costs	0	0	0	0
Integration and transaction-related costs	0	0	0	0
Charges associated with litigation matters			0	0
Charge for organizational efficiency plan				0
Contractual adjustment for a former client				0
Pre-tax adjusted income (loss) from operations	13	132	37	209
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net investment income	1	1	1	1
TOTAL REVENUES	(1,628)	(1,394)	(3,336)	(2,839)
Net realized investment results from certain equity method investments	0	0	0	0
Special item related to contractual adjustment for a former client				0
Adjusted revenues	(1,628)	(1,394)	(3,336)	(2,839)
Income before income taxes	(370)	(544)	(857)	(1,287)
Special items
Pre-tax adjusted income (loss) from operations	(344)	(400)	(698)	(805)
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	0	0	0	0
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	0	0	0	0
Net realized investment (gains) losses	0	0	0	0
Amortization of acquired intangible assets	0	0	0	0
Special items
Debt extinguishment costs	10	14	141	199
Integration and transaction-related costs	16	130	45	227
Charges associated with litigation matters			(27)	25
Charge for organizational efficiency plan				31
Contractual adjustment for a former client				0
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(1,629)	(1,395)	(3,337)	(2,840)
Intersegment Eliminations | Evernorth
Segment Reporting Information [Line Items]
Revenues from customers	(1,034)	(885)	(2,232)	(1,859)
Intersegment Eliminations | Integrated Medical
Segment Reporting Information [Line Items]
Revenues from customers	(595)	(504)	(1,105)	(970)
Intersegment Eliminations | International Markets [Member]
Segment Reporting Information [Line Items]
Revenues from customers	0	0	0	0
Intersegment Eliminations | Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ 0	$ (6)	$ 0	$ (11)

Segment Information - Revenue f

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from External Customer [Line Items]
Premiums	$ 10,323	$ 10,406	$ 20,537	$ 21,246
Total revenues from external customers	42,821	39,042	83,401	77,158
Integrated Medical
Revenue from External Customer [Line Items]
Total revenues from external customers	9,689	8,684	19,291	17,952
International Markets [Member]
Revenue from External Customer [Line Items]
Premiums	1,442	1,344	2,892	2,719
Total revenues from external customers	1,527	1,466	3,026	2,886
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenues	30,047	26,564	58,072	51,662
Network revenues
Revenue from External Customer [Line Items]
Revenues	15,414	13,090	29,593	25,232
Home delivery and specialty revenues
Revenue from External Customer [Line Items]
Revenues	13,014	12,183	25,472	23,897
Other
Revenue from External Customer [Line Items]
Revenues	1,619	1,291	3,007	2,533
U.S. Medical premiums | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	8,833	7,912	17,540	16,232
Health Insurance | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	3,578	3,090	7,101	6,551
Stop loss | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	1,194	1,152	2,388	2,313
Other | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	308	283	618	572
Medicare Advantage | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	2,116	1,904	4,208	3,785
Medicare Part D | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	410	420	860	882
Other | Integrated Medical
Revenue from External Customer [Line Items]
Premiums	1,227	1,063	2,365	2,129
Domestic disability, life and accident premiums
Revenue from External Customer [Line Items]
Premiums	0	1,124	0	2,240
Other premiums
Revenue from External Customer [Line Items]
Premiums	48	26	105	55
Total services
Revenue from External Customer [Line Items]
Revenues	2,451	2,072	4,792	4,250
Fees
Revenue from External Customer [Line Items]
Revenues	2,345	1,979	4,672	4,133
Other external revenues
Revenue from External Customer [Line Items]
Revenues	$ 106	$ 93	$ 120	$ 117

Segment Information - 10-Q Narr

Segment Information - 10-Q Narrative (Details) - USD ($) $ in Billions	Jun. 30, 2021	Dec. 31, 2020
Pharmacy Benefits Management Services | Performance Guarantee
Loss Contingencies [Line Items]
Performance guarantee liability	$ 1	$ 1.1